

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 170 594 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

09.01.2002 Bulletin 2002/02

(51) Int Cl.7: **G01N 33/88, G01N 33/566**

(21) Application number: **01305857.3**

(22) Date of filing: **06.07.2001**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: **07.07.2000 US 216796**

22.12.2000 US 257393

(71) Applicant: **Pfizer Products Inc.
Groton, Connecticut 06340 (US)**

(72) Inventors:

• **Bauer, Paul Harold
Arlington, Massachusetts 02476 (US)**

• **Ceng, John Bin,
Pfizer Global Research and Develop
Groton, Connecticut 06340 (US)**

• **Gladue, Ronald Paul
Groton, Connecticut 06340 (US)**

• **Li, Baiyong
Groton, Connecticut 06340 (US)**

• **Neote, Kuldeep Singh
Groton, Connecticut 06340 (US)**

• **Zhang, Jiansu
Roslindale, Massachusetts 02131 (US)**

(74) Representative: **Hayles, James Richard et al
Pfizer Limited, Patents Department, Ramsgate
Road
Sandwich Kent CT13 9NJ (GB)**

(54) **Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2**

(57) The present invention relates to the discovery that PGD₂ is the natural ligand for orphan receptor CRTH2, which interaction, it will now immediately be recognized, is important in the development of valuable

pharmaceuticals. The present invention is therefore related to methods for screening for therapeutic compounds useful in the treatment of PGD₂-related disorders such as allergy, asthma and inflammation. Appropriate assay methodology is also disclosed.

EP 1 170 594 A2

DescriptionField of the Invention

[0001] The present invention relates to the identification of compounds useful in the treatment and prevention of disease states mediated by prostaglandin D₂ ("PGD₂").

[0002] Prostaglandins are a class of compounds derived from the 20-carbon fatty acid skeleton of arachidonic acid which function as locally acting hormone-like chemical mediators. Prostaglandins define one major division of the eicosanoids, a large family of chemical mediators, derived from 20 carbon-polyunsaturated fatty acids, and which also includes the lipoxins, thromboxanes, hydroperoxy fatty acids, and leukotrienes.

[0003] In general, synthesis of eicosanoids is stimulated by local tissue damage, hormonal stimuli, or via cellular activation pathways (such as binding of IgE immunoglobulins to cell surface receptors). Unlike stored, pre-formed chemical mediators, eicosanoid lipid mediators typically appear in cells only after activation events. Eicosanoids, in turn, bind to specific cell surface receptors thereby mediating a wide variety of effects in numerous tissues. Prostaglandins are known to mediate many inflammatory responses and functions of the immune system. Antagonist compounds have been developed for various classes of eicosanoids that act to prevent the normal effects of eicosanoid-receptor binding.

[0004] Generally speaking, the inflammatory response is a protective mechanism that facilitates response to local injury. For example, leakage of tissue fluids into the affected area facilitates contact with antibodies, and also permits the migration of white blood cells to directly combat any injurious agent. Unfortunately, an inflammatory response may be inappropriate, that is, it may continue for an excessive period of time or involve participation by inflammatory system components that, unfortunately, act to damage to the body, thereby contributing to, or even defining, a disease state. Accordingly, there are numerous circumstances where it is medically appropriate to interfere with inflammatory processes. Allergies and asthma represent a major class of complex, and typically chronic, inflammatory disease. As is typical of many inflammatory disease states, allergic disease states also involve aberrant or otherwise undesired activation of the immune system.

[0005] The present invention is particularly directed to the identification of compounds useful in the prevention and treatment of allergic diseases, including allergic asthma, atopic dermatitis, and allergic rhinitis. The present invention is also directed generally to the identification of compounds useful in the prevention and treatment disease states involving inflammatory components including, without limitation, inflammatory disorders such as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; disorders of the skin including psoriasis, eczema, erythema, pruritis, and acne; stroke, and any disease marked by reperfusion injury, graft rejection, and autoimmune diseases.

Reported Developments

[0006] Allergic asthma and allergic rhinitis are diseases that currently affect about 10% of the population, and that number appears to be increasing (Bush, R.K.a.G., John W., Handbook of asthma and rhinitis. 1st ed. 1997, Abingdon: Blackwell Science. 270). Currently numerous classes of pharmaceutical agents are widely used to treat these diseases, for example, antihistamines, decongestants, β_2 agonists, anticholinergics, methylxanthines, cromolyns, corticosteroids, and leukotriene modulators. Generally however, the usefulness of these agents is limited by side-effects and low efficacy. Accordingly, there is a critical medical need to identify pharmaceutically active compounds that interfere with key steps of the inflammatory and immunological processes that contribute to these disease states, and other inflammatory conditions.

[0007] PGD₂ is known to be produced by platelets. It is also produced by mast cells, macrophages, and other cells that participate in inflammatory processes, and processes of the immune system. Reported functions of PGD₂ include inhibition of platelet aggregation, relaxation and constriction of smooth muscle, modulation of signal transmission in neurons, sleep induction, and facilitation of the chemotactic response of cells that mediate inflammatory response. Mast cells have long been associated with immunoglobulin type IgE-dependent allergic diseases, such as allergic rhinitis and allergic asthma. There is clear evidence that mast cell-derived mediators, such as PGD₂, leukotriene C₄, histamine, and proteases, cytokines and chemokines, contribute to immediate hypersensitivity reactions (for example, see Rossi and Olivieri, *Chest*, 112(2), pp. 523-529, 1997).

[0008] Besides mast cells, immune system helper T cells of type Th2 have been recognized as potential orchestrators of allergic responses (Wills-Karp, 1999, Annual Review of Immunology 17:255-81). In atopic patients, disease severity correlates with the level of Th2-produced cytokines, and Th2 cells have been identified in bronchoalveolar lavage and bronchial biopsy specimens (Robinson *et al.*, 1992, New England Journal of Medicine 326(5):298-304; Walker *et al.*, 1992, American Review of Respiratory Disease 146(1):109-15). Relief of symptoms by corticosteroids correlates well with the reduction of Th2 cytokines (for example, see Wilkinson *et al.*, 1991, International Archives of Allergy & Applied Immunology 94(1-4):220-1). Additionally, adoptive transfer of Th2 cells into IL-4 knockout mice has provided evidence that Th2 cells contribute to the pathogenesis of airway hyperresponsiveness (Li *et al.*, 1996, Journal of Immunology

157(8):3216-9; Brusselle *et al.*, 1995, American Journal of Respiratory Cell & Molecular Biology 12(3):254-9).

[0009] However, providing more specific and effective therapies for inflammatory conditions will require a better understanding of the specificity of each involved chemical mediator for cellular receptors, and the nature of resultant downstream signalling events. Although numerous receptors have been identified for prostaglandins (for example, DP, FP and EP), only the DP receptor has been shown to have specificity for PGD₂. Given the complexity of biological responses, it is highly likely that additional cellular receptor types for PGD₂ should exist, although recent isolation efforts in this regard have failed (see Narumiya *et al.*, 1999, Physiological Reviews 79(4):1193-226).

[0010] Recently it has been determined that PGD₂ is produced by human Th2 cells (Tanaka K, *et al.*, J Immunol, 164(5) pp. 2277-80, 2000). It has also been determined that Th2 cells express a particular G-protein coupled receptor, originally cloned from a human Th2 cell line (see Nagata *et al.*, 1999, Journal of Immunology 162(3):1278-86, and U. S. Patent 6,040,426, both of which are incorporated by reference herein). This receptor has been termed CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells). See also Gene Bank accession number AB008535.

[0011] The CRTH2 receptor is also selectively expressed from a wide variety of tissues including the brain, lung and lymphoid organs (Abe *et al.*, 1999, Gene 227(1):71-7). With respect to expression from immune system cells, it is reported that CRTH2 receptor is selectively expressed on Th2 cells, eosinophils and basophils, but not Th1 cells, B cells and NK cells (Nagata *et al.*, 1999, FEBS Letters 459(2):195-9). Additionally, there is no significant sequence homology between CRTH2 and any other known cell surface proteins, except for a low homology (~30%) with the FMLP receptor. Additionally, no natural ligand for CRTH2 has been reported.

[0012] The present invention is directed to the discovery that the natural ligand for CRTH2 is in fact PGD₂ which interaction, it will now immediately be recognized, is important in the development of specific anti-inflammatory pharmaceuticals.

Summary of the Invention

[0013] The present invention is directed to methods for screening for therapeutic compounds that are useful in the treatment of PGD₂-related disorders, such as allergy, asthma, and inflammation. The invention is based, in part, on the discovery as described herein that PGD₂ is a natural ligand for CRTH2, and the role of this interaction in allergic and inflammatory responses. In various embodiments, the invention provides primary screening assays to identify modulators, that is compounds that are antagonists and/or agonists, of PGD₂-CRTH2 interactions. These primary assays are adaptable to high-throughput screening.

[0014] In other embodiments, the invention provides secondary assays to further characterize the biological activity of such modulators (for example agonist or antagonist) and their resultant utilities. Certain identified compounds will be useful in the treatment and prevention of disorders and conditions in which PGD₂ participates, such as, for example, allergy, asthma, and generally, inflammation conditions. Certain identified compounds will be useful in the treatment and prevention of disorders and conditions where it is advantageous to enhance the interaction of PGD₂ and CRTH2.

[0015] The invention provides a method for identifying a compound that modulates a CRTH2-PGD₂-mediated process, comprising: a) contacting CRTH2 with a test compound, in the presence or absence of PGD₂; and b) determining the biological effects thereof. In a typical assay, the test compound will bind, and have effects, at the same site on CRTH2 at which PGD₂ normally binds, although the skilled practitioner will recognize that this need not always be so, that is, the methodologies of the present invention may also be used to identify compounds acting at sites on CRTH2 remote to the PGD₂ binding site.

[0016] In one embodiment, the compound identified is an antagonist which interferes with the interaction of PGD₂ with CRTH2, or the normal result thereof. In a further embodiment, the compound identified is an agonist which mimics the normal effects of binding of PGD₂ on CRTH2, but at an enhanced level. In a typical embodiment, the CRTH2 activity measured is the ability to interact with PGD₂. In additional embodiments of the invention, the test compound is an antibody specific for CRTH2, or is an antibody specific for an epitope provided in part by PGD₂.

[0017] The invention further provides a method for identifying a compound that modulates a CRTH2-PGD₂-mediated process comprising: a) contacting a CRTH2-expressing cell with a test compound; and b) measuring the resultant level of a CRTH2 activity, or the level of expression of CRTH2 in the cell, such that if said level of measured activity or expression differs from that measured in the absence of the test compound, then a compound that modulates a CRTH2-PGD₂-mediated process is identified. In one embodiment, the CRTH2 activity measured is the ability to interact with PGD₂. In another embodiment, the CRTH2 activity measured is the chemotactic response of the cell to PGD₂.

[0018] In another embodiment, this method further comprises: a) contacting a second cell which expresses CRTH2 with the identified compound; and b) determining whether the compound modulates a second CRTH2 activity. In yet another embodiment, either the first or the second CRTH2 activity measured is the ability to interact with PGD₂. In yet another embodiment, either the first or the second CRTH2 activity measured is the chemotactic response of the cell to PGD₂. In another embodiment, the second CRTH2 activity is the intracellular Ca²⁺ concentration, the release of reactive

oxygen species, or actin polymerization.

[0019] Also encompassed by the invention is a method for identifying a compound that modulates the binding of PGD₂ to CRTH2, comprising: (a) contacting the CRTH2 with PGD₂ (or an analog thereof) in the presence of a test compound; and (b) measuring the amount of PGD₂ (or analog) that is bound to CRTH2, such that if the amount of bound PGD₂ measured in (b) differs from the amount of bound PGD₂ measured in the absence of the test compound, then a compound that modulates the binding of PGD₂ to CRTH2 is identified. In one embodiment, the CRTH2 contacted in step (a) is on a cell surface. In another embodiment, the CRTH2 is immobilized to a solid surface. In another embodiment, the solid surface is a microtiter dish. In yet another embodiment, the amount of bound PGD₂ is measured by contacting the cell with a PGD₂-specific antibody.

[0020] In still another embodiment, the PGD₂ is labeled and the amount of bound PGD₂ is measured by detecting the label. In one embodiment of this method, the PGD₂ is labeled with a fluorescent label.

[0021] The invention further provides a method for detecting a CRTH2-PGD₂ related disorder in a mammal comprising measuring the either the level of CRTH2 gene expression, or of CRTH2 receptor, in a patient sample, such that if the measured level differs from the level found in clinically normal individuals, then a CRTH2-PGD₂ related disorder is detected.

[0022] Also encompassed by the present invention are kits. A kit is provided comprising (a) PGD₂ or an analog thereof, or (b) a CRTH2 polypeptide, or (c) nucleic acid encoding a CRTH2 polypeptide or, for example, (d) a cell expressing CRTH2, as packaged in a container with appropriate instructions and additional reagents. In one embodiment, the kit further comprises instructions for use in detecting the presence of a CRTH2-PGD₂ related disorder in a patient.

[0023] The term "PGD₂-mediated" as used herein includes processes that are dependent and/or responsive, either directly or indirectly, to the level of expression, synthesis and/or activity of PGD₂. Such processes include, but are not limited to allergic, asthmatic, and inflammatory processes, such as chemotaxis of inflammatory cells, inhibition of platelet aggregation, relaxation and constriction of smooth muscle, and neurological regulation, including sleep, body temperature and pain response regulation.

[0024] The terms "CRTH2-PGD₂-related disorder" and "CRTH2-PGD₂-related conditions" as used herein refer to disorders and conditions in which PGD₂ participates, or which may be affected, beneficially or adversely, by the concentration of PGD₂ in a patient. Such disorders and conditions may result, for example, from an aberrant level of PGD₂ expression, synthesis and/or activity relative to levels found in normal, unaffected, unimpaired individuals. Such disorders include, but are not limited to, allergic disorders, asthmatic disorders, and inflammatory disorders, such as allergic rhinitis, allergic asthma, bronchoconstriction; and neurological disorders, including sleep disorders; and disorders in the regulation of body temperature or pain response.

[0025] For the purposes of the present invention, an "analog" of PGD₂ is a compound generally similar in structure to PGD₂, and which generally has the same general biological effect as PGD₂, at least under one condition of assay. Thus, in an assay in which the activity of potential PGD₂-agonist or PGD₂-antagonist compounds will be measured, the analog may be substituted for any PGD₂ itself that would otherwise be used in said assay.

Brief Description of the Drawings

[0026]

- Figure 1 A. Scatchard plot analysis of the [³H]-PGD₂ binding to cells transfected with CRTH2.
B. The effects of the prostaglandins and their analogs on human eosinophil [³H]-PGD₂ binding site.
- Figure 2 Structures of Certain PGD₂ Derivatives.
- Figure 3 Chemotactic Response of PGD₂, mMDC and mSDF in Human T Lymphocytes.
- Figure 4 Chemotactic Response of Human Basophils to PGD₂ and C5a.
- Figure 5 Structures of PGD₂ Antagonists IAa-11 and BW-A 868C.
- Figure 6 Structures of prostaglandins and analogs.
- Figure 7A/B Structures of PGD₂ Agonists based on the PGD Ring.
- Figure 8 Structures of PGD₂ Agonists based on the PGF Ring.
- Figure 9 Structures of PGD₂ Agonists based on the PGJ Ring.
- Figure 10 A/B Structures of Certain PGD₂ antagonists.

Detailed Description of the Invention

[0027] Described herein are screening assays for the identification of therapeutic compounds useful for the detection and treatment of PGD₂-related disorders, such as allergenic disorders, asthma, and inflammatory response disorders. The assays are also adaptable for the detection of compounds that, relative to PGD₂ itself, show enhanced

PGD₂-CRTH2 binding and activity. Such screening assays include first, primary screening assays, which may be adapted to high-throughput screening formats, and, second, secondary screening assays, which can be used to further characterize lead compounds identified in the primary screens. In addition, there are disclosed diagnostic and therapeutic methods for the use of identified compounds in the treatment of PGD₂-related disorders.

[0028] The screening assays described herein may be used to identify, for example, organic compounds, peptides and proteins (including antibodies) that modulate the interaction of PGD₂ with CRTH2.

[0029] Such identified compounds, and the like, may be used as agonists or antagonists of the chemotactic induction of CRTH2 by PGD₂. For example, compounds that affect CRTH2 activity include but are not limited to compounds that bind to CRTH2, thereby inhibiting binding of PGD₂, and that either block chemotactic induction (antagonists) or enhance chemotactic induction (agonists).

[0030] The methodology of the present invention is also useful to detect (or confirm the activity of) compounds that bind to PGD₂, thereby preventing or enhancing binding of PGD₂ to CRTH2. The therapeutic activity of antibodies may be confirmed according to this aspect of the invention.

[0031] Compounds that affect CRTH2 gene activity (by affecting CRTH2 gene expression, including molecules, *e.g.*, proteins or small organic molecules, that affect transcription or interfere with splicing events so that expression of the full length or the truncated form of CRTH2 can be modulated) can also be identified in the screens of the invention.

[0032] Further, it should be noted that the assays described can also identify compounds that modulate CRTH2 signal transduction (*e.g.*, compounds which affect downstream signaling events, such as inhibitors or enhancers of G-protein activities which may participate in transducing the signal activated by PGD₂, or other ligand binding to CRTH2).

The identification and use of such compounds which affect signaling events downstream of CRTH2 and thus modulate effects of CRTH2 on allergic or inflammatory responses, for example, are within the scope of the invention.

[0033] The primary screening assays described herein are designed to detect compounds that modulate the PGD₂-CRTH2 interaction, that is, the test compounds act in the place of PGD₂ at the CRTH2 receptor, either negatively or positively compared with PGD₂, or which combine with or otherwise modify PGD₂, thereby affecting how it acts at the CRTH2 receptor. As described in detail below, such assays are functional assays, such as binding assays, that can be adapted to high-throughput screening methodologies.

[0034] Binding assays can be used to identify compounds that modulate the interaction between PGD₂ and CRTH2. In one aspect of the invention, the screens may be designed to identify compounds that interfere with the normal interaction between CRTH2 and PDG₂, such as other natural prostaglandins, or analogs thereof, or other compounds. Such compounds will be useful as lead compounds for antagonists of allergenic responses, asthma and inflammatory responses. In another aspect of the invention, the screens may be designed to identify compounds that mimic the normal interaction between CRTH2 and PDG₂, but with enhanced effect, such as other prostaglandins, or analogs thereof, or other compounds. Such compounds will be useful as lead compounds for agonists of the CRTH2-PDG₂ interaction.

[0035] Binding assays may be performed either as direct binding assays or as competition binding assays. In a direct binding assay, a test compound is tested for binding either to the CRTH2 receptor, or to ligand PGD₂. Then, in a second step, the test compound is tested for its ability to modulate the PGD₂-CRTH2 interaction. Competition binding assays, on the other hand, assess the ability of a test compound to compete with PGD₂ for binding to CRTH2.

[0036] In a direct binding assay, either PGD₂ and/or CRTH2 is contacted with a test compound under conditions that allow binding of the test compound to the ligand or the receptor. The binding may take place in solution or on a solid surface. Preferably, the test compound is previously labeled for detection. Any detectable group may be used for labeling, such as but not limited to, a luminescent, fluorescent, or radioactive isotope or group containing same, or a nonisotopic label, such as an enzyme or dye. After a period of incubation sufficient for binding to take place, the reaction is exposed to conditions and manipulations that remove excess or non-specifically bound test compound. Typically, this involves washing with an appropriate buffer. Finally, the presence of a PGD₂-test compound complex or a CRTH2-test compound complex is detected.

[0037] In a competition binding assay, test compounds are assayed for their ability to disrupt or enhance the binding of PGD₂ to CRTH2. Labeled PGD₂ may be mixed with CRTH2 or a fragment or derivative thereof, and placed under conditions in which the interaction between them would normally occur, either with or without the addition of the test compound. The amount of labeled PGD₂ that binds CRTH2 may be compared to the amount bound in the presence or absence of test compound.

[0038] In a preferred embodiment, to facilitate complex formation and detection, the binding assay is carried out with one or more components immobilized on a solid surface. In various embodiments, the solid support could be, but is not restricted to, polycarbonate, polystyrene, polypropylene, polyethylene, glass, nitrocellulose, dextran, nylon, polyacrylamide and agarose. The support configuration can include beads, membranes, microparticles, the interior surface of a reaction vessel such as a microtiter plate, test tube or other reaction vessel. The immobilization of CRTH2, or other component, can be achieved through covalent or non-covalent attachments. In one embodiment, the attachment may be indirect, *i.e.* through an attached antibody. In another embodiment, CRTH2 and negative controls are tagged

with an epitope, such as glutathione S-transferase (GST) so that the attachment to the solid surface can be mediated by a commercially available antibody such as anti-GST (Santa Cruz Biotechnology).

[0039] For example, such an affinity binding assay may be performed using a CRTH2 which is immobilized to a solid support. Typically, the non-immobilized component of the binding reaction, in this case either PGD₂ or the test compound, is labeled to enable detection. A variety of labeling methods are available and may be used, such as detection of luminescent, chromophoric, fluorescent, or radioactive isotopes or groups, or detection of nonisotopic labels, such as enzymes or dyes. In one preferred embodiment, the test compound is labeled with a fluorophore such as fluorescein isothiocyanate (FITC, available from Sigma Chemicals, St. Louis).

[0040] The labeled test compounds, or PGD₂ plus test compounds, are then allowed to contact with the solid support, under conditions that allow specific binding to occur. After the binding reaction has taken place, unbound and non-specifically bound test compounds are separated by means of washing the surface. Attachment of the binding partner to the solid phase can be accomplished in various ways known to those skilled in the art, including but not limited to chemical cross-linking, non-specific adhesion to a plastic surface, interaction with an antibody attached to the solid phase, interaction between a ligand attached to the binding partner (such as biotin) and a ligand-binding protein (such as avidin or streptavidin) attached to the solid phase, and the like.

[0041] Finally, the label remaining on the solid surface may be detected by any detection method known in the art. For example, if the test compound is labeled with a fluorophore, a fluorimeter may be used to detect complexes.

[0042] In a preferred embodiment, a binding assay can be performed as follows:

(a) 300-19 cells (see below) that transiently express CRTH2 are pelleted, and washed twice at room temperature with assay buffer (Hank's balanced saline, including Ca⁺² and Mg⁺², and supplemented with HEPES and sodium bicarbonate). The cells are resuspended at a concentration of 2 x 10⁷ cells/ml. Using 96-well U-bottom microtiter dishes, the assays are set up as follows (in 150 µl volumes):

(b) 50 µl of vehicle (as 0.3% DMSO in assay buffer, total wells); or 50 µl of 30 µM cold PGD₂ which results in a 10 µM final assay concentration thereof [the stock solution of cold PGD₂ was dissolved in DMSO at a stock concentration of 10 mM, and stored at -20°C, for use it was then diluted 3:1000 to final stock concentration of 30 µM];

50 µl cells (2 x 10⁷/ml for 10⁶/well);

50 µl of 6 nM [³H]-PGD₂ is added for a final concentration of 2 nM (Amersham; 162 Ci/mmol, 0.1 Ci/ml in methanol: water: acetonitrile (3:2:1), 617 nM diluted to 10 µl per ml assay buffer for a concentration of 6 nM).

(c) The plate is allowed to incubate for 20 min at room temperature before centrifugation (2800rpm, Sorval RT6000, 5 min, 4°C). The supernatant is discarded to decrease non-specific binding. The plate (Packard Unifilter plate GF/C, previously soaked in 3% PEI for at least 1 hr) is harvested with cold assay buffer by washing 6 times with 150 µl buffer wash per well. The filterplate is dried overnight. After the addition of 50 µl scintillation fluid, the plate is counted in a scintillation counter (1 min per well). (Preferably CRTH2 is added to binding assays in the form of intact cells that express CRTH2, or as isolated cell membranes that contain CRTH2. Thus, direct binding to CRTH2, or the ability of a test compound to modulate a PGD₂-CRTH2 complex, may be assayed in intact cells in culture, or in animal models, in the presence and absence of the test compound).

[0043] A labeled PGD₂ may be mixed with cells that express CRTH2, or with crude extracts obtained from such cells, and the test compound may be added. Isolated membranes may be used to identify compounds that interact with CRTH2. For example, in a typical experiment using isolated membranes, cells may be genetically engineered to express CRTH2. Membranes can be harvested by standard techniques and used in an *in vitro* binding assay. Labeled ligand (e.g., ¹²⁵I-labeled PGD₂) is bound to the membranes and assayed for specific activity; and specific binding is determined by comparison with binding assays performed in the presence of excess unlabeled (cold) ligand. Alternatively, soluble CRTH2 may be recombinantly expressed and utilized in non-cell based assays to identify compounds that bind to CRTH2. The recombinantly expressed CRTH2 polypeptide(s) or fusion proteins containing one or more of the ECDs of CRTH2 can be used in the non-cell based screening assays. Alternatively, peptides corresponding to one or more of the CDs of CRTH2, or fusion proteins containing one or more of the CDs of CRTH2, can be used in non-cell based assay systems to identify compounds that bind to the cytoplasmic portion of the CRTH2; such compounds may be useful to modulate the signal transduction pathway of the CRTH2. In non-cell based assays, the recombinantly expressed CRTH2 is attached to a solid substrate such as a test tube, microtitre well or a column, by means known to those in the art (see Ausubel *et al.*, supra). The test compounds are then assayed for their ability to bind to the CRTH2.

[0044] Alternatively, the binding reaction may be carried out in solution. In this assay, the labeled component is allowed to interact with its binding partner(s) in solution. If the size differences between the labeled component and its binding partner(s) permit such a separation, the separation can be achieved by passing the products of the binding reaction through an ultrafilter whose pores allow passage of unbound labeled component but not of its binding partner

(s) or of labeled component bound to its partner(s). Separation can also be achieved using any reagent capable of capturing a binding partner of the labeled component from solution, such as an antibody against the binding partner, a ligand-binding protein which can interact with a ligand previously attached to the binding partner, and so on.

[0045] In one embodiment, for example, a phage library can be screened by passing phage from a continuous phage display library through a column containing purified CRTH2, or derivative, analog, fragment, or domain, thereof, linked to a solid phase, such as plastic beads. By altering the stringency of the washing buffer, it is possible to enrich for phage that express peptides with high affinity for CRTH2. Phage isolated from the column can be cloned and the affinities of the short peptides can be measured directly. Sequences for more than one oligonucleotide can be combined to test for even higher affinity binding to CRTH2. Knowing which amino acid sequences confer the strongest binding to CRTH2, computer models can be used to identify the molecular contacts between CRTH2 and the test compound. This will allow the design of non-protein compounds which mimic those contacts. Such a compound may have the same activity of the peptide and can be used therapeutically, having the advantage of being efficient and less costly to produce.

[0046] In another specific embodiment of this aspect of the invention, the solid support is membranes containing CRTH2 attached to a microtiter dish. Test compounds, for example, cells that express library members are cultivated under conditions that allow expression of the library members in the microtiter dish. Library members that bind to the protein (or nucleic acid or derivative) are harvested. Such methods, are described by way of example in Parmley & Smith, 1988, Gene 73:305-318; Fowlkes *et al.*, 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in other references cited herein.

[0047] In another embodiment of the present invention, interactions between CRTH2 or PGD₂ and a test compound may be assayed *in vitro*. Known or unknown molecules are assayed for specific binding to CRTH2 nucleic acids, proteins, or derivatives under conditions conducive to binding, and then molecules that specifically bind to CRTH2 are identified. The two components can be measured in a variety of ways. One approach is to label one of the components with an easily detectable label, place it together with a test component(s) under conditions that allow binding to occur, perform a separation step which separates bound labeled component from unbound labeled component, and then measure the amount of bound component. In one embodiment, CRTH2 can be labeled and added to a test agent, using conditions that allow binding to occur. Binding of the test agent can be determined using polyacrylamide gel analysis to compare complexes formed in the presence and absence of the test agent.

[0048] In yet another embodiment, binding of PGD₂ to CRTH2 may be assayed in intact cells in animal models. A labeled PGD₂ may be administered directly to an animal, with and without a test compound. The uptake of PGD₂ may be measured in the presence and the absence of test compound. For these assays, host cells to which the test compound has been added may be genetically engineered to express the CRTH2 and/or PGD₂, which may be transient, induced or constitutive, or stable. For the purposes of the screening methods of the present invention, a wide variety of host cells may be used including, but not limited to, tissue culture cells, mammalian cells, yeast cells, and bacteria. Each cell type has its own set of advantages. Mammalian cells such as T cells or other cells that express CRTH2, i.e. brain, thymus, muscle, spleen, skin and other tissues, may be a preferred cell type in which to carry out the assays of the present invention. Bacteria and yeast are relatively easy to cultivate but process proteins differently than mammalian cells.

[0049] In some cases, a functional CRTH2 ligand may not form a thermodynamically stable complex with CRTH2, and would therefore not be detectable by primary assays which require the formation of stable binary complex. Such ligands, however, may be detectable by kinetic measurements of complex formation. It is known, for example, that PGD₂ binding to CRTH2 and to DP is differentially regulated by temperature and the presence of Ca²⁺ and Mg²⁺ ions. Such methods include, for example, kinetic measurement of on rates and off rates of ligand binding to the receptor. Thus, binding assays of the invention also include kinetic studies and measurements.

[0050] In addition, in some instances, responses of G protein-coupled receptors have been observed to subside, or become desensitized with prolonged exposure to ligand. In a further embodiment of the invention, assays may be utilized to identify compounds that block the desensitization of the CRTH2 receptor, and such compounds may be used to sustain the activity of CRTH2. Such compounds can be used as part of a therapeutic method for the treatment of PGD₂-related disorders, such as allergic and inflammatory response disorders, such as asthma.

[0051] In one embodiment of the invention, for example, an assay which is less dependent upon the formation of thermodynamically stable complexes is a scintillation proximity assay (described in U.S. patent no. 4,568,649). Purified or partially purified CRTH2 or CRTH2 membranes are coated onto the surface of a scintillant-loaded solid phase (e.g., beads) and the solid phase is treated with a blocking agent such as albumin or serum. Radiolabeled test compounds (e.g., ³³P-labeled) are then mixed with the CRTH2-coated beads, under conditions that would allow specific binding of a candidate specific binding test compound to the CRTH2 on the solid phase. After washing to remove excess or non-specific binding, if specific binding of a labeled test compound and CRTH2 took place, the radiolabel is brought into close proximity to the scintillant, allowing the scintillant to emit light, which is detectable with a scintillation counter.

[0052] In an alternative embodiment, an affinity capture scintillation proximity assay may be used so that binding

may be performed in solution. In this assay, CRTH2 is purified and labeled with an affinity label, such as biotin. Biotinylated CRTH2 is then mixed with the radiolabeled test compound, under conditions that allow solution binding to occur. Biotinylated CRTH2 including complexes of CRTH2 and test compound are captured on streptavidin-coated scintillant-loaded beads (available from Amersham) and counted in a scintillation counter, as described above.

[0053] Chemotaxis assays may also be used as primary assays. One biological effect of the interaction between a prostaglandin receptor of type CRTH2 and an attractant is the induction of the directional migration of cells expressing the receptor toward the particular attractant, a process known as chemotaxis. A chemotaxis assay, as described herein, may be used to screen compounds that interfere with the interaction of the CRTH2 receptor and the attractant PGD₂. Such chemotaxis assays are adaptable to high throughput screening methods, and can thus be used in as a primary assay to identify CRTH2 antagonists. A number of techniques have been developed to assay chemotactic migration (see, e.g., Leonard *et al.*, 1995, "Measurement of α and β Chemokines", in *Current Protocols in Immunology*, 6.12.1-6.12.28, Ed. Coligan *et al.*, John Wiley & Sons, Inc. 1995).

[0054] In one embodiment, for example, a compound can be tested for its ability to modulate the ability of PGD₂ to induce migration of cells that express CRTH2 using a chemoattractant gradient in a multiwell Boyden chemotaxis chamber. This apparatus typically contains a chamber bottom with 48 U-bottom wells, into which is placed the chemoattractant, or compound to be tested for chemoattractant activity. A polycarbonate membrane covered with a sealing gasket separates the bottom chamber from the 48-holed chamber top, into which a cell suspension is added to the wells formed by the membrane and the chamber top.

[0055] In a specific example of this method, a competitive assay is performed to test compounds for their ability to interrupt the attraction of CRTH2 cells to PGD₂. In this method, test compounds are diluted into the bottom wells of the Boyden chemotaxis chamber. A constant amount of PGD₂ is also added to this dilution series, at a concentration known to have a chemotactic effect on CRTH2 cells. As a control, at least one aliquot contains only PGD₂. Cells expressing CRTH2 are resuspended at 3-3.5 x 10⁶ cells/ml in RPMI 1640 supplemented with 10 mM HEPES and 1 mg/ml bovine serum albumin (Sigma, St. Louis, MO), and placed into the upper wells of the chamber. The chambers are incubated for 90-120 minutes at 37°C in a humidified CO₂ incubator. After the incubation period, the number of migrating cells on the lower surface of the membrane filter is counted using light microscopy. The contribution of the test compound to the chemotactic activity of PGD₂ is measured by comparing the chemotactic activity of the aliquots containing only PGD₂ with the activity of aliquots containing test compound and PGD₂. If addition of the test compound to the PGD₂ solution results in a decrease in the number of cells detected on the lower surface of the membrane relative to the number of cells detected using a solution containing only PGD₂, then there is identified an antagonist of PGD₂ induction of chemotactic activity of cells expressing CRTH2. In contrast, if the addition of the test compound to the PGD₂ solution results in a decrease in the number of cells detected on the lower surface of the membrane (relative to the number of cells detected using a solution containing only PGD₂), then an agonist of PGD₂ induction of chemotactic activity of cells expressing CRTH2 is identified.

[0056] The methods of the invention can routinely be performed in a high-throughput fashion for rapidly screening multiple test compounds. In particular, the cell systems used in such methods can be expressed and assayed in any multiple copy format known to those of skill in the art, including, but not limited to microtiter plates, spotting on agar plates, agar wells, spotting on chips and the like. Likewise, standard multiple manipulation techniques including but not limited to robotic handling techniques, can be utilized for multiple deposition of cells and/or test compounds.

[0057] After identification of a test compound that modulates the interaction of PGD₂ with CRTH2, secondary screening assays may be used to further characterize the test compound for its effect on the biological activity of PGD₂, CRTH2, and PGD₂-CRTH2 signaling pathways. Various assays can be adapted to use as a secondary screen. For example, such methods include, but are not limited to, binding assays, chemotaxis assays, adhesion assays, intracellular calcium mobilization assays, oxygen release assays, and actin polymerization assays. Examples of such assays are discussed in detail hereinbelow.

[0058] Binding assays may be performed as a secondary assay, instead of, or in addition to a primary binding assays. In one embodiment, where a direct binding assay was used as a primary screen, a competition assay may be used as a secondary screen. In another embodiment, a binding assay may be used for a compound identified by a functional primary screen, such as a high-throughput chemotaxis screening assay. In another embodiment, a compound identified in a primary screen using a binding assay may be further analyzed in a secondary screen using a second type of binding assay. For example, a compound identified using a CRTH2 affinity column assay, may be tested in a secondary screen by kinetic analysis of its binding interaction.

[0059] The chemotaxis assay may be used as a secondary assay. A test compound identified by the primary screening assay to interfere with the binding of PGD₂ to CRTH2, or, alternatively, to enhance the binding of PGD₂ to CRTH2, can be tested for biological activity using a chemotaxis assay. As described above, chemokines can induce directional migration of cells via their interaction with a cell-type specific chemokine receptor, and a number of techniques have been developed to test this chemotactic migration (see, e.g., Leonard *et al.*, 1995, "Measurement of α and β Chemokines", in *Current Protocols in Immunology*, 6.12.1-6.12.28, Ed. Coligan *et al.*, John Wiley & Sons, Inc. 1995). Thus,

in one embodiment, for example, a compound can be tested for its ability to modulate the ability of PGD₂ to induce migration of cells that express CRTH2 using a chemokine gradient in a multiwell Boyden chemotaxis chamber.

[0060] In a specific example of this method, a serial dilution of a PGD₂/CRTH2 antagonist or agonist test compound identified in the primary screen is placed in the bottom wells of the Boyden chemotaxis chamber. A constant amount of PGD₂ is also added to this dilution series. As a control, at least one aliquot contains only PGD₂. The method and the assay conditions are as described in the primary screening assay, and the number of migrating cells on the lower surface of the membrane filter is counted using light microscopy. The contribution of the antagonist or agonist compound to the chemotactic activity of PGD₂ is measured by comparing the chemotactic activity of the aliquots containing only PGD₂ with the activity of aliquots containing test compound and PGD₂. If addition of the test compound to the PGD₂ solution results in a decrease in the number of cells detected on the lower surface of the membrane relative to the number of cells detected using a solution containing only PGD₂, then an antagonist of PGD₂ induction of chemotactic activity of cells expressing CRTH2 is identified. In contrast, if the addition of the test compound to the PGD₂ solution results in a decrease in the number of cells detected on the lower surface of the membrane relative to the number of cells detected using a solution containing only PGD₂, then an agonist of PGD₂ induction of chemotactic activity of cells expressing CRTH2 is identified.

[0061] Another secondary assay is the reactive oxygen species release assay. One measure of PGD₂-induced activation of CRTH2 cells, such as eosinophils, is the intracellular release of reactive oxygen species. This can be tested in a reactive oxygen species release assay, or ROS, using lucigenin-dependent chemiluminescence to measure reactive oxygen species release. In this method, freshly isolated eosinophils are prepared, by standard methods, and resuspended at concentration 2-4 x 10⁶ cells/ml in (RPMI; 10mM HEPES; 1x Pen/Strep; 0.5% FBS) at room temperature. Immediately prior to use, 1ml of cell suspension is added to 9ml of buffer, prewarmed to 37°C for 15 minutes, and added 0.5ml of 200mM Lucigenin.

[0062] Test compounds (made as 10,000x DMSO stocks) are diluted in buffer with DMSO (1.5μl of DMSO/2.5ml Buffer) and 25 μl/well added to white 96-well culture plate and placed in a 37°C incubator. Isolated cells (held at room temperature) are diluted with room temperature buffer to 2-4 X 10⁶ cells/ml, and incubated in a water bath at 37°C for 15 minutes. At 15 minutes, 0.5ml 200mM lucigenin (bis-N-Methylacridinium Nitrate; Sigma, St. Louis, MO) is added to 10 ml of the cell suspension, mixed, and 100 μl /well is added to the prewarmed microtiter plate. The plate is returned to 37°C for 5 minutes, at which time 25 μl of stimulus is added. The plate is read in the luminometer for 8 cycles. The luminescence of test compounds can be tested in the presence of PGD₂, relative to a control sample containing PGD₂ alone. A compound that interferes with the ability of PGD₂ to result in intracellular reactive oxygen species release in CRTH2 cells, is a candidate for a CRTH2 antagonist.

[0063] Another secondary screening assay is the calcium mobilization assay. Elevation in intracellular ionized calcium concentration ([Ca²⁺]_i) is an early indicator of chemotactic activation. Indeed, in calcium flux studies described below, it is demonstrated that even low levels of PGD₂ increase [Ca²⁺]_i mobilization in cells that express CRTH2. Such calcium flux assays can be used as secondary screens to further characterize modulators of PGD₂/CRTH2 interactions. Intracellular calcium ion concentrations can be measured in cells that express CRTH2 in the presence of PGD₂, and/or in the presence and the absence of a test compound.

[0064] Calcium mobilization can be detected and measured by flow cytometry, and by labeling with fluorescent dyes that are trapped intracellularly. For example, the dye Indo-1 exhibits a change in emission spectrum upon binding to calcium. The ratio of fluorescence produced by the calcium-bound dye to that produced by the unbound dye is used to estimate the intracellular calcium concentration. In one embodiment, for example, the following method can be used. Cells that express CRTH2 are collected, and resuspended in fresh media at ~2x10⁵/ml the day before performing the calcium flux assay. Cells are incubated at 37°C for not longer than 20-30 minutes, and then spun down and resuspended in 50ml fresh PTI buffer (Hank's Buffer, pH 7.2-7.4; 10mM Hepes; 1.6mM CaCl₂) containing Indo-1 AM, pre-warmed to 37°C, at a concentration of 10 million per ml. Cells are excited, and fluorescence is measured using a fluorimeter (Photon Technology Corporation, International). After the readout has stabilized, the time axis is reset, and PGD₂ is added at a specific time point (e.g., 20 seconds). After response, the following reagents are added to the cuvette, to release and chelate total calcium, in the following order: 20μl of 18% Triton X-100, 20μl of 3M Tris, pH 8.5, and 20μl of 0.5M EGTA, pH 8.5. The experiment is repeated in the presence and the absence of a test compound. In the absence of test compound, PGD₂ results in increased ([Ca²⁺]_i) in cells that express CRTH2, with an EC₅₀ of 15 nM. Therefore, in the presence of an agonist test compound, the EC₅₀ would be expected to be higher than this value, whereas in the presence of an agonist test compound, the EC₅₀ would be expected to decrease.

[0065] Yet another secondary screening assay is an actin polymerization assay. Another biological effect of the interaction of PGD₂ with CRTH2 is actin polymerization. Thus, an actin polymerization assay may be used as a secondary screen to characterize the activity of a compound isolated in the primary screening assays of the invention. In one embodiment, actin polymerization may be assayed using an actin-specific fluorescent label, nitrobenzoxadiazole (NBD)-phalloidin, which binds polymerized actin fiber. In a specific embodiment, the assay may be performed as follows: cell preparations are resuspended at 5-10 x 10⁶ cells/ml in RPMI 1640 plus 10mM HEPES, 100/10 Pen/Strep,

and 0.5% FCS. The cell suspension is aliquoted (100 μ L per well) into a 96-well U-bottom polypropylene microtiter plate. 50 μ L of the appropriate stimulus (PGD₂ or test compound, or both PGD₂ and test compound) is added using an 8-channel pipette followed exactly 25 seconds later by 50 μ L of a stopping solution which contains lysophosphatidylcholine (0.5mg/ml), Hank's balanced salt solution (100 μ L 10x), 16 % formaldehyde (800 μ L), and 6.8 μ M NBD-phalloidin choline (0.5mg/ml). The plate is allowed to sit at room temperature for 15 minutes. The plate is then centrifuged at 1000rpm for 5 minutes, the supernatants flicked off and the cell pellets resuspended in 250 μ L PBS plus 2%FCS and 0.2% sodium azide. Each sample is then read on a FACS Caliber instrument. Cells are gated using the forward scatter/ side scatter data in the lymphocyte area. Responses are measured by the change in median FL-1 fluorescence between vehicle treated cells and stimulus treated cells. Test compounds can be assayed in the presence and absence of PGD₂ and compared to a sample containing PGD₂ alone. A compound that reduces PGD₂-induced actin polymerization of CRTH2 cells is identified as a candidate CRTH2 antagonist.

[0066] The screening assays described herein may be used to identify organic compounds, or peptides or proteins, for example, that modulate the interaction of the PGD₂ with CRTH2. The substances which may be screened in accordance with the invention therefore also include antibodies and fragments thereof. Peptidomimetic organic compounds that bind, for example, to the extra-cellular domain (ECD) of CRTH2 and either inhibit the activity triggered by the natural ligand (*i.e.*, antagonists) or mimic the activity triggered by the natural ligand (*i.e.*, agonists), may also be screened. Additionally, organic compounds, peptides, antibodies or fragments thereof, to which the ECD (or a portion thereof) of CRTH2 is covalently attached may also bind to and therefore "neutralize" PGD₂, otherwise the natural CRTH2 ligand. Screening of such complex reagents is also within the practice of the invention.

[0067] Compounds that may be used for screening include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, *e.g.*, Lam *et al.*, 1991, Nature 354:82-84; Houghten *et al.*, 1991, Nature 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, *e.g.*, Songyang *et al.*, 1993, Cell 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')₂ and Fab expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

[0068] In one embodiment of the present invention, peptide libraries may be used as a source of test compounds that can be used to screen for modulators of HSPR interactions. Diversity libraries, such as random or combinatorial peptide or nonpeptide libraries can be screened for molecules that specifically bind to the HSP receptor. Many libraries are known in the art that can be used, *e.g.*, chemically synthesized libraries, recombinant (*e.g.*, phage display libraries), and *in vitro* translation-based libraries.

[0069] Examples of chemically synthesized libraries are described in Fodor *et al.*, 1991, Science 251:767-773; Houghten *et al.*, 1991, Nature 354:84-86; Lam *et al.*, 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12: 709-710; Gallop *et al.*, 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten *et al.*, 1992, Biotechniques 13:412; Jayawickreme *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

[0070] Examples of phage display libraries are described in Scott & Smith, 1990, Science 249:386-390; Devlin *et al.*, 1990, Science, 249:404-406; Christian, *et al.*, 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay *et al.*, 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.

[0071] By way of examples of nonpeptide libraries, a benzodiazepine library (see *e.g.*, Bunin *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostrash *et al.* (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

[0072] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, *e.g.*, the following references, which disclose screening of peptide libraries: Parnley & Smith, 1989, Adv. Exp. Med. Biol. 251: 215-218; Scott & Smith, 1990, Science 249:386-390; Fowlkes *et al.*, 1992, BioTechniques 13:422-427; Oldenburg *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu *et al.*, 1994, Cell 76:933-945; Staudt *et al.*, 1988, Science 241: 577-580; Bock *et al.*, 1992, Nature 355:564-566; Tuerk *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington *et al.*, 1992, Nature 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner *et al.*; Rebar & Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318.

[0073] In another embodiment of the present invention, the screening may be performed by adding the labeled PGD₂ to *in vitro* translation systems such as a rabbit reticulocyte lysate (RRL) system and then proceeding with *in vitro* priming reaction. *in vitro* translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

[0074] Compounds that can be tested and identified methods described herein can include, but are not limited to, compounds obtained from any commercial source, including Aldrich (1001 West St. Paul Ave., Milwaukee, WI 53233), Sigma Chemical (P.O. Box 14508, St. Louis, MO 63178), Fluka Chemie AG (Industriestrasse 25, CH-9471 Buchs, Switzerland (Fluka Chemical Corp. 980 South 2nd Street, Ronkonkoma, NY 11779)), Eastman Chemical Company, Fine Chemicals (P.O. Box 431, Kingsport, TN 37662), Boehringer Mannheim GmbH (Sandhofer Strasse 116, D-68298 Mannheim), Takasago (4 Volvo Drive, Rockleigh, NJ 07647), SST Corporation (635 Brighton Road, Clifton, NJ 07012), Ferro (111 West Irene Road, Zachary, LA 70791), Riedel-deHaen Aktiengesellschaft (P.O. Box D-30918, Seelze, Germany), PPG Industries Inc., Fine Chemicals (One PPG Place, 34th Floor, Pittsburgh, PA 15272). Further any kind of natural products may be screened using the methods of the invention, including microbial, fungal, plant or animal extracts.

[0075] Furthermore, diversity libraries of test compounds, including small molecule test compounds, may be utilized. For example, libraries may be commercially obtained from Specs and BioSpecs B.V. (Rijswijk, The Netherlands), Chembridge Corporation (San Diego, CA), Contract Service Company (Dolgoprudny, Moscow Region, Russia), Comgenex USA Inc. (Princeton, NJ), Maybridge Chemicals Ltd. (Cornwall PL34 OHW, United Kingdom), and Asinex (Moscow, Russia).

[0076] Still further, combinatorial library methods known in the art, can be utilized, including, but not limited to: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, *Anticancer Drug Des.* 12:145). Combinatorial libraries of test compounds, including small molecule test compounds, can be utilized, and may, for example, be generated as disclosed in Eichler & Houghten, 1995, *Mol. Med. Today* 1:174-180; Dolle, 1997, *Mol. Divers.* 2:223-236; and Lam, 1997, *Anticancer Drug Des.* 12:145-167.

[0077] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:6909; Erb *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.*, 1994, *J. Med. Chem.* 37:2678; Cho *et al.*, 1993, *Science* 261:1303; Carrell *et al.*, 1994, *Angew. Chem. Int. Ed. Engl.* 33:2059; Carrell *et al.*, 1994, *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.*, 1994, *J. Med. Chem.* 37:1233.

[0078] Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992, *Bio/Techniques* 13:412-421), or on beads (Lam, 1991, *Nature* 354:82-84), chips (Fodor, 1993, *Nature* 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores (Patent Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or phage (Scott and Smith, 1990, *Science* 249:386-390; Devlin, 1990, *Science* 249:404-406; Cwirla *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87:6378-6382; and Felici, 1991, *J. Mol. Biol.* 222:301-310).

[0079] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, *e.g.*, the following references, which disclose screening of peptide libraries: Parmley & Smith, 1989, *Adv. Exp. Med. Biol.* 251: 215-218; Scott & Smith, 1990, *Science* 249:386-390; Fowlkes *et al.*, 1992, *Bio/Techniques* 13:422-427; Oldenburg *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:5393-5397; Yu *et al.*, 1994, *Cell* 76:933-945; Staudt *et al.*, 1988, *Science* 241: 577-580; Bock *et al.*, 1992, *Nature* 355:564-566; Tuerk *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:6988-6992; Ellington *et al.*, 1992, *Nature* 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner *et al.*, Rebar & Pabo, 1993, *Science* 263:671-673; and PCT Publication No. WO 94/18318.

[0080] Among the test compounds that can be tested are compounds, including small organic molecule compounds that are known in the art to act as prostaglandin inhibitors.

[0081] Upon identification of a compound that modulates the interaction of PGD₂ with CRTH2, such a compound can be further investigated to test for an ability to alter the allergenic or inflammatory response. In particular, for example, the compounds identified via the present methods can be further tested *in vivo* in accepted animal models of PDG₂-related disorders, such as, *e.g.*, allergy, asthma, and inflammation.

[0082] Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate the interaction of PGD₂ with CRTH2. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

[0083] Next, the three dimensional geometric structure of the active site (typically a binding site) is determined. This can be done by known methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

[0084] If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

[0085] Finally, having determined the structure of the active (binding) site, either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active (binding) site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential CRTH2-modulating compounds.

[0086] Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active (binding) site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

[0087] Further experimental and computer modeling methods useful to identify modulating compounds based upon identification of the active (binding) sites of either CRTH2 or PGD₂ and related prostaglandins and their analogs, will be apparent to those of skill in the art.

[0088] Examples of molecular modeling systems are the CHARMM and QUANTA programs (Polygen Corporation, Waltham, MA). CHARMM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modelling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

[0089] A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotininen *et al.*, 1988, *Acta Pharmaceutica Fennica* 97:159-166; Ripka (1988 *New Scientist* 54-57); McKinlay and Rossmann (1989, *Annu. Rev. Pharmacol. Toxicol.* 29:111-122); Perry and Davies, OSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 Alan R. Liss, Inc. 1989; Lewis and Dean (1989, *Proc. R. Soc. Lond.* 236:125-140 and 141-162); and, with respect to a model receptor for nucleic acid components, Askew, *et al.* (1989, *J. Am. Chem. Soc.* 111:1082-1090). Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc. (Pasadena, CA.), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario). Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.

[0090] CRTH2 protein, polypeptides and peptide fragments, mutated, truncated or deleted forms of the CRTH2 and/or CRTH2 fusion proteins can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in diagnostic assays, the identification of other cellular gene products involved in the regulation of PGD₂-related disorders, as reagents in assays for screening for compounds that can be used as pharmaceutical reagents in the treatment of PGD₂-related disorders. Additionally, based upon information gained from interacting CRTH2 and PGD₂, peptide fragments of CRTH2 can be derived which inhibit the normal binding of circulating PGD₂ to CRTH2 receptors molecules, for *in vivo* therapeutic use.

[0091] CRTH2 peptides, polypeptides, and fusion proteins can be prepared by recombinant DNA techniques. For example, nucleotide sequences encoding one or more of the four domains of the ECD of the serpentine CRTH2 can be synthesized or cloned and ligated together to encode a soluble ECD of the CRTH2. The DNA sequence encoding one or more of the four ECDs can be ligated together directly or via a linker oligonucleotide that encodes a peptide spacer. Such linkers may encode flexible, glycine-rich amino acid sequences thereby allowing the domains that are strung together to assume a conformation that can bind CRTH2 ligands. Alternatively, nucleotide sequences encoding individual domains within the ECD can be used to express CRTH2 peptides.

[0092] A variety of host-expression vector systems may be utilized to express nucleotide sequences encoding the appropriate regions of CRTH2 to produce such polypeptides. Where the resulting peptide or polypeptide is a soluble derivative (e.g., peptides corresponding to the ECDs; truncated or deleted in which the TMs and/or CDs are deleted), the peptide or polypeptide can be recovered from the culture media. Where the polypeptide or protein is not secreted, the CRTH2 product can be recovered from the host cell itself.

[0093] The host-expression vector systems also encompass engineered host cells that express CRTH2 or functional equivalents *in situ*, i.e., anchored in the cell membrane. Purification or enrichment of CRTH2 from such expression

systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of CRTH2, but to assess biological activity, e.g., in drug screening assays.

[0094] The host-expression vector systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing CRTH2 nucleotide sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing CRTH2 nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing CRTH2 sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing CRTH2 nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[0095] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the CRTH2 gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of CRTH2 protein or for raising antibodies to the CRTH2 protein, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther *et al.*, 1983, EMBO J. 2:1791), in which the CRTH2 coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509), and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0096] Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht *et al.* allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht *et al.*, 1991, Proc. Natl. Acad. Sci. USA 88: 8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺-nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

[0097] In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The CRTH2 coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of a CRTH2 gene coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). The recombinant viruses are then used to infect cells in which the inserted gene is expressed (e.g., see Smith *et al.*, 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

[0098] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the CRTH2 nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the CRTH2 gene product in infected hosts (see, e.g., Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted CRTH2 nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire CRTH2 gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the CRTH2 coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in frame with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc (see Bittner *et al.*, 1987, Methods in Enzymol. 153:516-544).

[0099] In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and

processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. Accordingly, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3 and WI38 cell lines.

[0100] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the CRTH2 sequences described above may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the CRTH2 gene product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the CRTH2 gene product.

[0101] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler *et al.*, 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy *et al.*, 1980, Cell 22:817). genes can be employed in tk⁻, hgprt⁻ or aprt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler *et al.*, 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, *et al.*, 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981, J. Mol. Biol. 150:1); and hygromycin (Santerre *et al.*, 1984, Gene 30:147).

[0102] Antibodies that specifically recognize one or more epitopes of CRTH2, or epitopes of conserved variants of CRTH2, or peptide fragments of CRTH2 are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab)₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-id) antibodies, and epitope-binding fragments of any of the above.

[0103] The antibodies of the invention may be used, for example, in the detection of CRTH2 in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of CRTH2. Antibodies that specifically recognize mutant forms of CRTH2, may be particularly useful as part of a diagnostic or prognostic technique. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes, as described, above, for the evaluation of the effect of test compounds on expression and/or activity of the CRTH2 gene product. Additionally, such antibodies can be used in conjunction with the gene therapy techniques described, below, e.g., to evaluate the normal and/or engineered CRTH2-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for the inhibition of abnormal CRTH2 activity. Thus, such antibodies may, therefore, be utilized as part of PGD₂-related disorder treatment methods.

[0104] For the production of antibodies, various host animals may be immunized by injection with CRTH2, a CRTH2 peptide (e.g., one corresponding to a functional domain of the receptor, such as ECD, TM or CD), truncated CRTH2 polypeptides (CRTH2 in which one or more domains, e.g., the TM or CD, has been deleted), functional equivalents of CRTH2 or mutants of CRTH2. Such host animals may include but are not limited to rabbits, mice, hamsters and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

[0105] Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497 and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor *et al.*, 1983, Immunology Today 4:72; Cole *et al.*, 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole *et al.*, 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. Production of high titers of mAbs *in vivo* makes this the presently preferred method of production.

[0106] In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger *et al.*, 1984, Nature, 312:604-608; Takeda *et al.*, 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

[0107] Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242:423-426; Huston *et al.*, 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward *et al.*, 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against CRTH2 gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

[0108] Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

[0109] Antibodies to CRTH2 can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" CRTH2, using techniques well known to those skilled in the art (see, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to the CRTH2 ECD and competitively inhibit the binding of PGD₂ to the CRTH2 can be used to generate anti-idiotypes that "mimic" the ECD and, therefore, bind and neutralize PGD₂. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize the native ligand and treat PGD₂-related disorders, such as allergic disorders and asthma.

[0110] Alternatively, antibodies to CRTH2 that can act as agonists of CRTH2 activity can be generated. Such antibodies will bind to the CRTH2 and activate the signal transducing activity of the receptor. In addition, antibodies that act as antagonist of CRTH2 activity, i.e. inhibit the activation of CRTH2 receptor would be particularly useful for treating PGD₂-related disorders, such as allergic disorders, asthma, and inflammatory disorders.

[0111] Genetically engineered cells that express soluble CRTH2 ECDs or fusion proteins e.g. fusion Ig molecules can be administered *in vivo* where they may function as "bioreactors" that deliver a supply of the soluble molecules. Such soluble CRTH2 polypeptides and fusion proteins, when expressed at appropriate concentrations, should neutralize or "mop up" the native ligand for CRTH2, and thus act as inhibitors of CRTH2 activity and may therefore be used to treat PGD₂-related disorders, such as allergic disorders, asthma, and inflammatory disorders.

[0112] CRTH2 is a cell surface protein present on certain T cells, brain, thymus, muscle, spleen, skin, and possibly other cell types, that appears to respond to PGD₂ released from mast cells, and possibly other cell types, an important early step in signal to be involved in PGD₂-related disorders. As such, CRTH2 may be important early step in allergic and inflammatory responses. Therefore, CRTH2 protein, analogs, derivatives, and fragments thereof, as well as nucleic acids (and sequences complementary thereto), and anti-CRTH2 antibodies, have uses in detecting and diagnosing such PGD₂-related disorders.

[0113] CRTH2 and CRTH2 nucleic acids can be used in assays to detect, prognose, or diagnose PGD₂-related disorders that may result in chronic, acute, or abnormal allergic and inflammatory responses, e.g., asthma.

[0114] The molecules of the present invention can be used in assays, such as immunoassays, to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting CRTH2 expression, or monitor the treatment thereof. In particular, such an immunoassay is carried out by a method comprising contacting a sample derived from a patient with an anti-CRTH2 antibody under conditions such that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody. In a specific aspect, such binding of antibody, in tissue sections, can be used to detect aberrant CRTH2 localization or aberrant (e.g., low or absent) levels of the CRTH2. In a specific embodiment, antibody to CRTH2 can be used to assay a patient tissue or serum sample for the presence of CRTH2 where an aberrant level of CRTH2 is an indication of a diseased condition. By "aberrant levels," is meant increased or decreased levels relative to that present, or a standard level representing that present, in an analogous sample from a portion of the body or from a subject not having the disorder.

[0115] The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, immunohistochemistry, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.

[0116] CRTH2 genes and related nucleic acid sequences and subsequences, including complementary sequences, can also be used in hybridization assays. CRTH2 nucleic acid sequences, or subsequences thereof, comprising about at least 8 nucleotides, can be used as hybridization probes. Hybridization assays can be used to detect, prognose,

diagnose, or monitor conditions, disorders, or disease states associated with aberrant changes in CRTH2 expression and/or activity as described supra. In particular, such a hybridization assay is carried out by a method comprising contacting a sample containing nucleic acid with a nucleic acid probe capable of hybridizing to CRTH2 DNA or RNA, under conditions such that hybridization can occur, and detecting or measuring any resulting hybridization.

[0117] In specific embodiments, diseases and disorders involving decreased immune responsiveness during an infection or malignant disorder can be diagnosed, or their suspected presence can be screened for, or a predisposition to develop such disorders can be detected, by detecting decreased levels of CRTH2 protein, CRTH2 RNA, or CRTH2 functional activity (e.g., binding to PGD₂, anti-CRTH2 antibody-binding activity etc.), or by detecting mutations in CRTH2 RNA, DNA or CRTH2 protein (e.g., translocations in CRTH2 nucleic acids, truncations in CRTH2 gene or protein, changes in nucleotide or amino acid sequence relative to wild-type CRTH2) that cause decreased expression or activity of CRTH2. Such diseases and disorders include but are not limited to allergic and asthmatic disorders (e.g., allergic rhinitis, allergic asthma, bronchoconstriction), neurological disorders (including sleep disorders, and disorders in the regulation of body temperature or pain response) and inflammatory disorders (for example, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; disorders of the skin including psoriasis, eczema, erythema, pruritis, and acne; stroke, and any disease marked by reperfusion injury, graft rejection, and autoimmune diseases).

[0118] By way of example, levels of CRTH2 can be detected by immunoassay, levels of CRTH2 RNA can be detected by hybridization assays (e.g., Northern blots, *in situ*-hybridization), and CRTH2 activity can be assayed by measuring binding activities *in vivo* or *in vitro*. Translocations, deletions, and point mutations in CRTH2 nucleic acids can be detected by Southern blotting, FISH, RFLP analysis, SSCP, PCR using primers that preferably generate a fragment spanning at least most of the CRTH2 gene, sequencing of CRTH2 genomic DNA or cDNA obtained from the patient, etc.

[0119] In a preferred embodiment, levels of CRTH2 mRNA or protein in a patient sample are detected or measured relative to the levels present in an analogous sample from a subject not having the PGD₂-related disorder, such as an allergic disorder, asthma, or inflammatory disorder. Decreased levels indicate that the subject may develop, or have a predisposition to developing, an allergic disorder, asthma, or inflammatory disorder.

[0120] In a specific embodiment, levels of CRTH2 mRNA or protein in a patient sample are detected or measured, relative to the levels present in an analogous sample from a subject not having the disorder, in which increased levels indicate that the subject has, or has a predisposition to, an autoimmune disorder.

[0121] Kits for diagnostic use are also provided, that comprise in one or more containers an anti-CRTH2 antibody, and, optionally, a labeled binding partner to the antibody. Alternatively, the anti-CRTH2 antibody can be labeled (with a detectable marker, e.g., a chemiluminescent, enzymatic, fluorescent, or radioactive moiety). A kit is also provided that comprises in one or more containers a nucleic acid probe capable of hybridizing to CRTH2 RNA. In a specific embodiment, a kit can comprise in one or more containers a pair of primers (e.g., each in the size range of 6-30 nucleotides) that are capable of priming amplification [e.g., by polymerase chain reaction (see e.g., Innis *et al.*, 1990, PCR Protocols, Academic Press, Inc., San Diego, CA), ligase chain reaction (see EP 320,308) use of Q β replicase, cyclic probe reaction, or other methods known in the art] under appropriate reaction conditions of at least a portion of a CRTH2 nucleic acid. A kit can optionally further comprise in a container a predetermined amount of a purified PGD₂ or CRTH2 nucleic acid, protein, derivative, analog, or fragment thereof, or, e.g., for use as a standard or control.

[0122] The invention encompasses methods and compositions for modifying the interaction with PGD₂ and CRTH2, and for treating PGD₂-related disorders, including, but not limited to, allergy, asthma, and inflammation. Because a loss of normal CRTH2 gene product function may result in the development of a PGD₂-related disorder phenotype, an increase in CRTH2 gene product activity, or activation of the CRTH2 pathway (e.g., downstream activation) would facilitate progress towards a normal PGD₂-related state in individuals exhibiting a deficient level of CRTH2 gene expression and/or CRTH2 activity.

[0123] Alternatively, symptoms of certain PGD₂-related disorders may be ameliorated by decreasing the level of CRTH2 gene expression, and/or CRTH2 gene activity, and/or downregulating activity of the CRTH2 pathway (e.g., by targeting downstream signaling events). Different approaches are discussed below.

[0124] A CRTH2 antagonist can be used to treat conditions such as asthma or inflammation. Agonists of CRTH2 can be used to stimulate CRTH2 activity, in mammals in need of such treatment.

[0125] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0126] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form

employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50} (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0127] Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

[0128] Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

[0129] For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

[0130] Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

[0131] For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0132] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0133] The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0134] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0135] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0136] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

Example 1

[0137] The *in vivo* and *in vitro* assays described in this Example characterize the PGD_2 /CRTH2 interaction, identifying PGD_2 as the key endogenous ligand for CRTH2.

[0138] Using 300-19 cells (transformed pre-B lymphocytes) expressing CRTH2, a number of mast cell and non-mast cell-derived mediators were screened in a $[Ca^{2+}]_i$ mobilization assay. (300-19 cells are disclosed in M.G. Reth et al., Nature, 317(6035), pp. 353-365, 1985). For the experiments herein, CRTH2 was expressed from a plasmid "p3.1 prolacflag" which contains ampicillin and neomycin resistance markers, and is driven by the CMV promoter. A prolac

signalling peptide allows membrane expression of the gene insert, with a Flag peptide tag at the N terminal permitting convenient detection of the expressed molecule. A preferred level of expression of CRTH2 is about 40,000 molecules/cell surface.

[0139] Calcium flux studies demonstrated that PGD₂ increased [Ca²⁺]_i mobilization in a CRTH2 stable cell line with an EC₅₀ of 15 nM. In contrast, PGJ₂ had an EC₅₀ of 200 nM in this test, whereas other prostaglandins and their analogs (PGE₂, PGF₂α, BW-245C, and thromboxane mimetics) and leukotrienes were found to be inactive (with EC₅₀'s greater than 300 nM).

[0140] To directly determine the binding affinity of CRTH2 for PGD₂, the following binding assay was used. Transfected and parental 300-19 cells were washed twice at room temperature with assay buffer, and resuspended at a concentration of 2 x 10⁷ cells/ml. Using a 96-well U-bottom polypropylene plate (Costar, Corning Inc., Acton, MA), the assay was set up as follows: 50 µl of vehicle (0.3% DMSO in assay buffer, total wells) or of 30 mM cold PGD₂ (NS wells); 50 µl cells (2 x 10⁷ cells/ml for 10⁶ cells per well); 50 µl 6 nM [³H]-PGD₂. The plate was allowed to incubate for 20 min at RT before centrifugation (2800rpm, Sorval RT6000, 5 min, 4°C). The plate was harvested (Packard Unifilter plate GF/C, previously soaked in 3% PEI for at least 1 hr) with cold assay buffer using a Packard Filtermate Cell Harvester (6 x 150 µl buffer wash per well). The filterplate was dried overnight. After the addition of 50 µl scintillation fluid (Packard Microscint 0), the plate was counted in a Packard Topcount scintillation counter (1 min per well). The IC₅₀ value for this binding has been determined to be 18 nM. The solutions of labeled PGD₂ and unlabeled "cold" PGD₂ were prepared as follows: 10 µl of [³H]-PGD₂ (Amersham lot # TRK734 162 Ci/mmol, 0.1 Ci/ml in methanol: water: acetonitrile (3:2:1), 617 nM) per ml assay buffer was used to prepare a solution of [³H]-PGD₂ at a concentration of 6 nM (50 µl/well for final conc. of 2 nM); cold PGD₂ (Biomol #PG-005, lot # P4653) was dissolved in DMSO for a stock of 10 mM (stored at -20°C). The 10 mM stock was diluted 3:1000 to obtain a final concentration of 30 mM (50 µl/well for final conc. of 10 mM). Assay buffer: Hank's balanced saline supplemented with HEPES and sodium bicarbonate: 100 mM/L of 10X Hank's Balanced Saline (with Ca²⁺, Mg²⁺); 10 mM/L of 1M HEPES; 4.7 mM/L of 7.5% Sodium Bicarbonate.

[0141] Figure 1A shows a Scatchard plot analysis of the [³H]-PGD₂ binding. This data indicated that the ligand bound to the transfectant with a homogenous population of receptors with a K_d = 18.1 nM. The receptor concentration was calculated to be 79,554 sites/cell.

[0142] The ability of PGD₂ to bind CRTH2, and to stimulate a PGD₂ response in cells expressing CRTH2, was compared with that of other prostaglandins and prostaglandin analogs. First, prostaglandins and analogs were tested for their ability to compete with PGD₂ for binding to CRTH2, using competition binding studies. These studies indicated the following rank of agonist potency among the prostaglandins and analogs tested: PGD₂ >> PGJ₂ > PGF₂ = PGE₂ >> BW245C. Next, comparative calcium release assays were performed. Figure 1B shows the effects of the PGD₂, PGJ₂, PGF₂, PGE₂, and BW245C on [Ca²⁺]_i mobilization in the transfectant. The order of [Ca²⁺]_i mobilization is similar to the order of their binding affinities as shown in Figure 1B, i.e., PGD₂ > PGF₂ >> BW245C.

[0143] As is shown in Figure 1B, the effects of the prostaglandins and analogs on human eosinophil [³H]-PGD₂ binding site and eosinophil functional responses have the same order of potency (i.e., PGD₂ > PGF₂ >> BW245C). This agonist rank order of potency differs significantly from that of any known prostanoid receptors, and is consistent with their interactions with CRTH2 (see Table 1).

[0144] The amino acid sequence alignment of human CRTH2 with other prostaglandin receptors, DP, EP 1-4, TP, FP, and IP, can be determined from published sources. CRTH2 shows less than 30% sequence homology with the DP, EP 1-4, TP, FP and IP receptors.

[0145] The chemotactic response of human T lymphocytes to PGD₂, murine MDC and murine mSDF was also assayed. Chemotaxis was determined using a 48-well Boyden chamber (Neuroprobe, Cabin John, MD), and 3.0 µm polycarbonate filters. Cells were resuspended (3-3.5 x 10⁶ cells/ml) in RPMI 1640 supplemented with 10 mM HEPES and 1 mg/ml bovine serum albumin (Sigma, St. Louis, MO), and placed into the upper wells of the chamber. The compound to be tested was placed in the lower wells. The chambers were incubated for 90-120 minutes at 37°C in a humidified CO₂ incubator. At the end of the incubation period, the number of migrating cells on the filter (expressed per high power field) were enumerated microscopically. As shown in Figure 3, both anti-CD3 stimulated T cells (upper panel) and anti-CD3 and anti-CD28 -stimulated T cells respond specifically to PGD₂. In Figure 4, the chemotactic response of human basophils to PGD₂ and C5a is shown.

Table 1.

The effect of PGD ₂ and other prostanoids on [³ H]-PGD ₂ binding and functional responses in isolated human eosinophils.					
Ligand	PGD ₂ binding IC ₅₀ (μM)	ROS* release EC ₅₀ (μM)	Chemotaxis EC ₅₀ (μM)	Actin-polymer* EC ₅₀ (μM)	[Ca ²⁺] _i mobilization EC ₅₀ (μM)
PGD ₂	0.025 (4)	0.002 (6)	0.003 (1)	0.004 (4)	0.03 (4)
PGJ ₂	OT	0.075(1)	>0.1 (1)	1.8 (1)	0.13(2)
PGF ₂ α	1.5(1)	>1 (3)	>0.1 (1)	1.9 (1)	>1 (1)
BW-245C	>100 (3)	>1 (1)	>1 (1)??	>1 (1)??	>1 (1)
Pa, 11b-PGF ₂	OT	>0.1 (2)	>0.1 (1)	>1 (2)	OT
PGE ₁	OT	>0.1 (1)	>0.1 (1)	>100 (1)	>1 (1)
PGE ₂	3.3 (1)**	>0.1 (1)**	>0.1 (1)**	>300 (2)**	>1 (2)**
PGI ₂	OT	>1 (2)	>0.1 (1)	>100 (1)	>1 (1)
U-46619	OT	>0.1 (2)	OT	OT	>1 (1)

*ROS: Reactive Oxygen Species; Actin-polymer: Human whole blood eosinophil actin-polymerization response

** Despite its binding to CRTH2, PGE₂ fails to induce eosinophil response (*i.e.*, actinpolymerization). It is hypothesized that PGE₂ may blunt CRTH2-mediated eosinophil response by its binding to EP₂ receptors (cAMP-mediated).

[0146] In connection with performing screens according to the practice of the present invention, it should be noted that the specific binding of PGD₂ to CRTH2 is higher at room temperature than at 40°C. In contrast, the specific binding of PGD₂ to the DP receptor is higher at 40°C than at room temperature. It should also be noted that small concentrations of magnesium and calcium ions enhance the binding of PGD₂ to CRTH2, while slightly inhibiting binding thereof to the DP receptor. With respect to enhancing interaction of PGD₂ with the CRTH2 receptor, 5mM of calcium or magnesium ions is a useful concentration, and generally between 1-50 mM, preferably 5-20 mM, will be of benefit.

Example 2

[0147] The following experiments were performed to further characterize CRTH2, and to determine the role of CRTH2 in PGD₂-mediated inflammatory responses.

[0148] CRTH2 is a member of the 7-transmembrane G protein-coupled class of receptors. As a G protein-coupled receptor, CRTH2 is coupled through G-proteins to cytoplasmic mediated events. Interestingly, pertussis toxin inhibited PGD₂-mediated eosinophil chemotaxis, suggesting that CRTH2 probably links with Gi. Studies also indicated that CRTH2 uses calcium as the second messenger but not cAMP.

[0149] In humans, CRTH2 has a broad tissue distribution, it is expressed in the brain, thymus, muscle, spleen, skin and other tissues. It is thus possible that CRTH2 may have different effects in different tissues, activating a particular gene product or activity in one cell type, and downregulating the same or another gene product or activity in another tissue, depending on the signal transduction pathway activated in that particular cell type.

[0150] Given topically to guinea pig eyes, PGD₂ elicits ocular hypotension and a microvascular leakage followed by conjunctival inflammation (eosinophil infiltration, mucus secretion) at 6-hour post challenge (Woodward *et al.*, 1990, Invest. Ophthalmol. Visu. Sci. 31:38-146). The ocular hypotension reaction was mimicked by BW-245C, whereas the microvascular leakage followed by conjunctival inflammation was BW-245C-insensitive, indicating that the inflammatory response was mediated via another receptor, possibly CRTH2.

[0151] The CRTH2-mediated increase in vascular permeability may be a key component of cellular inflammation and this action can greatly facilitate the *in vivo* chemotactic response to a chemotactic factor. In dogs, tracheal instillation and this action can greatly facilitate the *in vivo* chemotactic response to a chemotactic factor. In dogs, tracheal instillation causes eosinophil accumulation in the lumen of their trachea at 1 to 4 hrs post challenge (Emery *et al.*, 1989, Journal of Applied Physiology 67(3):959-62), and IV infusion produce a marked and rapid reduction in circulating eosinophils. In all of these studies there were no changes in neutrophil responses post PGD₂ challenge, an observation consistent with the lack of CRTH2 expression in neutrophils, and the fact that the radioligand receptor binding assay was not able to identify a specific binding site for 2nM [³H]-PGD₂ in purified human neutrophils.

[0152] *In vitro* studies with isolated human eosinophils demonstrated that activation of [Ca²⁺]_i mobilization, ROS release, actin-polymerization response and chemotaxis is most likely mediated via CRTH2 because of the similar rank

orders of agonist potencies in these studies compared with those obtained *in vitro* from the [3 H]-PGD₂ binding study with CRTH2 transfectant (see Example 1). But eosinophil activation by PGD₂ is clearly not mediated through FP or TP receptors since PGF₂ct or the known thromboxane mimetic U46619 do not show any activity in these assays. In addition to eosinophils, human activated T-lymphocytes and basophils were also responsive to PGD₂, and not to other prosta-

noids or BW-245C (see Figures 4 and 5) in chemotaxis assays.

[0153] Human activated T cells were demonstrated to respond to PGD₂, and that response to PGD₂ required the activation of T cells with CD3 and CD28. It is not yet known whether this response is restricted only to Th2 cells. Although CRTH2 was originally reported to be a Th2-specific receptor in human, studies in mice have indicated that both Th2 and Th1 cells express CRTH2 and respond to PGD₂. These studies suggest that there may be some differences in the CRTH2 expression pattern between species.

[0154] PGD₂ has many other biological effects pertinent to allergy, asthma, and inflammation. For example, inhaled PGD₂ causes bronchoconstriction in asthmatics, which effect is 3.5X and 30X more potent than PGF₂ct and histamine, respectively (Hardy *et al.*, 1984, New England Journal of Medicine 311(4):209-13). This effect is preferential on peripheral rather than central airways (Wasserman *et al.*, 1977, Prostaglandins 13(2): 255-69). Inhaled PGD₂ also causes coughing, and potentiates methacholine and histamine airway hyperreactivity in asthmatics. PGD₂ given intracutaneously to human skin elicits a strong erythema formation for up to 2 hours (Soter *et al.*, 1983, Journal of Investigative Dermatology 80(2):115-9), reflecting an increase in venular permeability. Intranasal challenge of atopic and nonatopic subjects with PGD₂ causes a dose-dependent decrease in nasal patency, and increase in allergic symptoms (nasal congestion, cough and sore throat, in particular), thus mimicking pathophysiologicals and symptoms associated with allergic rhinitis (Soter *et al.*, 1983, Journal of Investigative Dermatology 80(2):115-9). In C57/BL mice, antigen- and compound 48/80-induced in skin itching is blocked by PGD₂ antagonists. However, because of the lack of a complete pharmacological characterization of these responses, it is not clear which prostanoid receptor(s) is involved. *In vitro* and *in vivo* studies suggest that the bronchoconstrictive response by PGD₂ could be partly due to a direct activation of airway smooth muscle TP receptor (Beasley *et al.*, 1989, Journal of Applied Physiology 66(4):1685-93) or an indirect stimulation of a prejunctional release of acetylcholine from airway parasympathetic nerves (Tamaoki *et al.*, 1987, Journal of Applied Physiology 63(4):1396-400). The former seems unlikely since PGD₂ binds to the TP receptor with a low affinity (K_i = 75 μ M); and the latter does not offer the information with regards to which prostanoid receptor is involved.

[0155] Modulators, i.e. antagonists and agonists of PGD₂ and CRTH2 interactions may also be important in treatment of pulmonary diseases. PGD₂ can function as a key mediator in allergy, asthma, and inflammation, and is one of the most abundant mediators produced by mast cells (besides histamine and peptidoleukotrienes), and is recovered from BAL of atopic asthmatics and nasal lavage from allergic rhinitis (Knani *et al.*, 1992, Journal of Allergy & Clinical Immunology 90(6 Pt 1):880-9). In addition, patients with allergic rhinitis and asthma often do not get an effective relief of nasal congestion and pulmonary dysfunction even with the medications sold under the trademarks ZYRTEC and SIN-35 nase, indicating a mediator(s) other than histamine and leukotrienes is involved. It is possible that antigen-induced, mast-cell derived early release of PGD₂ may play a role in contributing to allergic symptoms as well as initiating inflammatory responses by recruiting eosinophils, lymphocytes and basophils into lungs. It appears that the BAL, and levels of PGD₂ and its metabolites in urine, are also significantly elevated after 12 hours post antigen challenge. Therefore, PGD₂ may also be involved in maintaining and potentially amplifying immune response by attracting more inflammatory cells.

[0156] Further kinetic studies revealed that anti-IgE triggers an early (2-30 min) and late (4-6 hrs) production of PGD₂ where the former is controlled by COX-1 and the later is regulated by inducible COX-2 (Reddy *et al.*, 1999, Biochemical & Biophysical Research Communications 265(1): 205-10). In fact, human Th2 cells and activated alveolar macrophages have recently been shown to synthesize PGD₂ by a COX-2 dependent pathway (Tamaoki *et al.*, 1987, Journal of Applied Physiology 63(4):1396-400; MacDermot *et al.*, 1984, Prostaglandins 27(2):163-79). Immunohistochemistry studies show a significant increase in bronchial epithelium and submucosal cellular expression of COX-2, but not of COX-1 in asthmatics (Sousa *et al.*, 1997, Thorax 52(11): 940-5). Since the kinetics of PGD₂ production is temporally correlated with early and late phase responses seen in antigen-challenged asthmatics, it is expected that mast cells, Th2 cells and activated alveolar macrophages are cell types that contribute to the surge of the levels of PGD₂ in the late phase.

Example 3

[0157] Figure 2 presents results of the calcium flux assay (again using 300-19 CRTH2 transfectants) for close analogs of PGD₂.

Example 4Additional assay to measure binding of PGD₂ agonists and antagonists to CRTH2

[0158] The binding of PGD₂ agonist and antagonist compounds was also measured using membranes prepared from CRTH2-expressing L1.2 cells. To make the membrane preparation, 10 grams of cell pellet are resuspended in 20 ml of cold 50 mM Tris HCl (pH 7.7), and homogenized three times (10 seconds each) on ice with a Polytron tissue homogenizer. The suspension is then diluted to 80 ml with the same buffer, and centrifuged at 40,000 x g for 30 min. After discarding the supernatant, the pellet is washed once with cold 80 mM Tris HCl (pH 7.7) by repeating the resuspension, homogenization, and centrifugation described above. Finally, the pellet is resuspended in 20 ml of cold 50 mM Tris HCl (pH 7.7), aliquoted, and stored at - 80°C. On the day of the assay, the membranes are thawed on ice, and 25 µl is placed into each well of a 96-well microtiter plate. 5 µl of 0.5 M MgCl₂ and 10 µl of PVT-WGA scintillation proximity assay (SPA) beads (Amersham) are then added to each well and mixed thoroughly. 5 µl of the compounds to be tested are then added, followed by 5 µl of 30 nM ³H-PGD₂ (200 Ci/mmol from NEN diluted 1:17) to initiate the binding reaction. The plate is then sealed and incubated at room temperature for at least 1 hour before being counted on a Wallac Microbeta Trilux scintillation counter. Non-specific binding is measured in wells containing 100 µM unlabeled PGD₂. Active compounds are able to compete with ³H-PGD₂ for binding to CRTH2 and are identified by a decrease in the number of cpm bound.

Example 5Additional assay to measure functional activity (agonist versus antagonist) of compounds at CRTH2

[0159] The functional activity of compounds was measured by their ability to block the transient Ca²⁺ flux induced by PGD₂ in L1.2 cells expressing CRTH2. The Ca²⁺ flux is measured with the FLIPR by using the FLIPR Calcium Assay Kit (Molecular Devices). First, a 1X solution of the Reagent Buffer is made by diluting Component B from the kit 1:10 and adjusting the pH to 7.4 with NaOH. Second, the Ca²⁺ Sensing Dye is prepared by dissolving 1 vial of Component A from the kit in 10 ml of 1X Reagent Buffer. On the day of the assay, 20 ml of 1X Reagent Buffer is mixed with 20 ml of Dulbecco's Modified Eagle Media (DMEM), 400 µl of 250 mM probenecid, and 1 ml of the Ca²⁺ Sensing Dye solution to produce the Assay Buffer. Cells are then pelleted by centrifugation at 1000 x g for 5 minutes, and approximately 90% of the old culture media is removed by aspiration. The cells are then resuspended in Assay Buffer to a concentration of 3.3 x 10⁵ cells/µl, and 60 µl of this suspension is placed into each well of a 384-well plate. The cell plate is incubated at 37°C for 1 hour in 5% CO₂, and then 5 µl of the compounds to be tested are added. The cell plate is then placed into the FLIPR along with a plate containing 1.4 µM PGD₂. The FLIPR automatically adds 5 µl of PGD₂ (the final concentration is 100 nM) to the cell plates, and measures the subsequent Ca²⁺ flux over a period of 2 minutes. Compounds that are able to inhibit the production of this Ca²⁺ flux are antagonists.

Example 6

[0160] The compounds depicted in Figure 7A/B, based on the PGD ring, were tested for selectivity for the CRTH2 receptor (in comparison with DP).

[0161] In the assay, the capacity of each D-ring compound to compete with binding of ³H-PGD₂ was measured at both the CRTH2 and DP receptors, and an IC₅₀ value (in µM) was determined. In the controls, using cold PGD₂ to compete with ³H-PGD₂, the IC₅₀ value of 0.0107 was determined (8 trials) at CRTH2, and a value of 0.0234 was determined at the DP receptor (7 trials). The binding assay procedure of Example 1 was used. Preferably, the ratio of IC₅₀ at CRTH2 to IC₅₀ at DP is less than about twenty, and more preferably is less than about two hundred.

[0162] The compounds 13,14-dihydro-15-keto PGD₂; 15(R)15-methyl PGD₂; and 15-deoxy-delta 12, 14, PGD₂ were particularly selective for CRTH2. The compounds depicted in Figure 7A/B were determined to be PGD₂ agonists in separate assays.

Example 7

[0163] The compounds depicted in Figure 8, based on the PGF ring, were similarly tested, and showed selectivity for the CRTH2 receptor (in comparison with DP). The compounds depicted in Figure 8 were determined to be PGD₂ agonists in separate assays.

Example 8

[0164] The compounds depicted in Figure 9, based on the PGJ ring, were similarly tested for selectivity for the CRTH2 receptor (in comparison with DP). The compounds depicted in Figure 9 were determined to be PGD₂ agonists in separate assays.

Example 9

[0165] The four compounds, (a) to (d), depicted in Figure 10 were similarly tested for selectivity for the CRTH2 receptor (in comparison with DP). The compounds were determined to be PGD₂ antagonists in separate assays (see Example 5).

[0166] With respect to synthesis of the compounds of this Example, the first compound, Figure 10(a), was reported in the chemical literature (Sindelar, K. et al.; Collect. Czech. Chem. Commun., 40, pp. 3530-3544, 1975) and its synthesis is straightforward.

[0167] The methyl ester of the steroid compound of Figure 10(b) has been prepared (see I.G. Reshetova et al., Bull. Acad. Sci. USSR Div. Chem. Sci. (English Translation), 39; 3.2; pp. 607-609, 1990; and also Izv. Akad. Nauk SSSR Ser. Khim.; RU; 3; pp. 687-690, 1990).

[0168] Compound 3, Figure 10(c), may be synthesized via a route analogous to that described in C. Menciú et al., J. Med. Chem.; 42(4), pp. 638 - 648, 1999.

[0169] Compound 4, Figure 10(d), is synthesized as described in B.L. Mylari et al., J. Med. Chem.; 34; pp. 108-122, 1991.

Claims

1. A method for identifying a compound that modulates the binding of PGD₂ to CRTH2 receptor comprising:

- (a) contacting a sample of CRTH2 with PGD₂ and measuring the binding of PGD₂ thereto;
- (b) contacting a similar sample of CRTH2 with both PGD₂ and also an appropriate amount of the test compound, and measuring the binding of PGD₂ to said CRTH2; and
- (c) comparing the results in (a) and (b) to determine if the binding of PGD₂ is affected by the presence of PGD₂.

2. A method for identifying a compound that modulates an activity of CRTH2 receptor that is normally dependent upon the binding of PGD₂ thereto, comprising the steps of:

- (a) contacting a sample of CRTH2 with PGD₂ and measuring a resultant activity of said CRTH2;
- (b) contacting a similar sample of CRTH2 with PGD₂ in the presence also of an appropriate amount a test compound, and measuring said resultant activity of CRTH2; and
- (c) comparing the results in (a) and (b) to determine if the PGD₂-dependent activity of CRTH2 is affected by the presence of said test compound.

3. The method of Claim 2, in which the test compound is identified as an antagonist that interferes with the PGD₂-dependent activity of CRTH2.

4. The method of Claim 2, wherein the test compound is an antibody specific for CRTH2.

5. The method of Claim 2, wherein the test compound is an antibody is specific for PGD₂.

6. The method of Claim 2, wherein the test compound is an agonist that enhances the PGD₂-dependent activity of CRTH2.

7. The method of Claim 2, in which the PGD₂-dependent activity of CRTH2 participates in a disease state that is selected from the group consisting of: allergic asthma, atopic dermatitis, allergic rhinitis, autoimmune disease, reperfusion injury, and inflammatory disease.

8. The method of claim 7, wherein said inflammatory disease is selected from the group consisting of rheumatoid arthritis; osteoarthritis; inflammatory bowel disease; a disorder of the skin selected from psoriasis, eczema, erythema, pruritis, and acne; stroke; and graft rejection.

9. The method of Claim 2, wherein the CRTH2 activity measured is the ability to bind to PGD₂.

10. The method of claim 2, wherein said CRTH2 is present on the surface of a mammalian cell, a membrane fragment thereof, or a lipid vesicle.

11. The method of Claim 10, wherein the CRTH2 is present on the surface of a mammalian cell, and the PGD₂-dependent activity of said CRTH2 is the chemotactic response of said cell to PDG₂.

12. The method of Claim 10, wherein the CRTH2 is present on the surface of a mammalian cell, and the PGD₂-dependent activity of CRTH2 is an affect on (a) intracellular Ca²⁺ concentration, (b) the release of reactive oxygen species, or (c) an effect on actin polymerization.

13. The method of Claim 2 wherein the CRTH2 is immobilized to a solid surface.

14. The method of Claim 13 wherein said solid surface is a microtiter dish.

15. A method for diagnosing a CRTH2-PGD₂ related disorder in a mammal comprising measuring the level of:


- (a) CRTH2 gene expression, or
- (b) a PGD₂-dependent activity of CRTH2,

in a patient sample, and comparing said measurement to that determined from clinically normal individuals.

16. A diagnostic kit comprising PGD₂, or analog thereof, and a CRTH2 polypeptide, nucleic acid encoding a CRTH2 polypeptide, or cell expressing CRTH2, packaged in a container.

17. The kit of Claim 16, further comprising instructions for use in detecting or treating a CRTH2-PGD₂ related disorder in a patient.

18. Use of a compound that modulates an activity of CRTH2 receptor that is normally dependent upon the binding of PGD₂ thereto for the manufacture of a medicament for the treatment of allergic asthma, atopic dermatitis, allergic rhinitis, autoimmune disease, reperfusion injury, and inflammatory diseases such as rheumatoid arthritis; osteoarthritis; inflammatory bowel disease; a disorder of the skin selected from psoriasis, eczema, erythema, pruritis, and acne; stroke; and graft rejection.

**FIG. 1A**

Comparison of [^3H]PGD₂ binding results in human eosinophils and CRTH2 and DP transfectants.

	CRTH2 transfectant IC ₅₀ , uM	Human eosinophils IC ₅₀ , uM	DP transfectant IC ₅₀ , uM
PGD ₂	0.015 (4)	0.025 (4)	0.022 (3)
PGF ₂ α	0.98 (1)	1.5 (1)	8.75 (1)
PGE ₂	1.6 (1)	3.3 (1)	6.76 (1)
BW-245C	>100 (3)	>100 (3)	0.01 (2-3)

FIG. 1B

PGD₂ Derivatives

Structure	Chemical Name	IC50 in Ca flux assay
	13,14-dihydro-15 keto-PGD ₂	26 nM
	16,16-dimethyl- PGD ₂	16 nM
	15(S)-15-methyl- PGD ₂	16 nM

under similar circumstances, PGD₂ itself tested at about 15.2 nM

FIG. 2




FIG. 3A

Human CD4 T cells were isolated from PBMC and stimulated with anti-CD3 and/or anti-CD28 for 4 days and chemotaxis assay was performed using PGD2, murine MDC and murine SDF.




FIG. 3B

Chemotactic response of human basophils to PGD₂ and C5a




FIG. 4

The structure of two PGD₂ antagonists:






FIG. 5


PGD2




9a, 11b-PGF2




PGI2




PGE1




BW-245C



PGE2



PGF2α



PGI2




FIG. 6





FIG. 7A

**FIG. 7B**




FIG. 8






FIG. 9




[4-Chloro-2-(4-chloro-phenylsulfanyl)-phenyl]-acetic acid.
Ratio of CRTH2 IC₅₀ to DP IC₅₀ is less than 1:40.




4-(3-Acetoxy-4,4,10,13,14-pentamethyl-7-oxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-pentanoic acid.
Ratio of CRTH2 IC₅₀ to DP IC₅₀ is less than 1:30.

FIG. 10 A



(1-Benzothiazol-2-ylmethyl-5-fluoro-2-methyl-1H-indol-3-yl)-acetic acid.
Ratio of CRTH2 IC_{50} to DP IC_{50} is less than 1:40.



[3-(6-Hydroxy-benzothiazol-2-ylmethyl)-4-oxo-3,4-dihydro-phthalazin-1-yl]-
acetic acid. Ratio of CRTH2 IC_{50} to DP IC_{50} is less than 1:20.

FIG. 10 B

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 170 594 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
06.08.2003 Bulletin 2003/32

(43) Date of publication A2:
09.01.2002 Bulletin 2002/02

(21) Application number: 01305857.3

(22) Date of filing: 06.07.2001

(51) Int Cl.7: **G01N 33/88**, G01N 33/566,
G01N 33/74, A61K 31/557,
A61K 31/5575, A61K 31/192,
A61K 31/575, A61K 31/502,
C07D 277/64

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 07.07.2000 US 216796
22.12.2000 US 257393

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(72) Inventors:
• **Bauer, Paul Harold**
Arlington, Massachusetts 02476 (US)
• **Ceng, John Bin,**
Pfizer Global Research and Develop
Groton, Connecticut 06340 (US)

- **Gladue, Ronald Paul**
Groton, Connecticut 06340 (US)
- **Li, Balyong**
Groton, Connecticut 06340 (US)
- **Neote, Kuldeep Singh**
Groton, Connecticut 06340 (US)
- **Zhang, Jiansu**
Roslindale, Massachusetts 02131 (US)

(74) Representative:
Dufresne, Guillaume Alain François
Pfizer Global Research & Development
Fresnes Laboratoires
3-9 rue de la Loge
B.P. 100
94265 Fresnes Cedex (FR)

(54) **Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2**

(57) The present invention relates to the discovery that PGD₂ is the natural ligand for orphan receptor CRTH2, which interaction, it will now immediately be recognized, is important in the development of valuable pharmaceuticals. The present invention is therefore re-

lated to methods for screening for therapeutic compounds useful in the treatment of PGD₂-related disorders such as allergy, asthma and inflammation. Appropriate assay methodology is also disclosed.

EP 1 170 594 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application Number

EP 01 30 5857

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IntCl.7)
P, X	WO 01 14882 A (BML INC ;HIRAI HIROYUKI (JP); NAGATA KINYA (JP); OGAWA KAZUYUKI (J) 1 March 2001 (2001-03-01) * the whole document * -8 EP 1 211 513 A (BML INC (JP)) 6 May 2002 (2002-05-06) * the whole document * ---	1-18	G01N33/88 G01N33/566 G01N33/74 A61K31/557 A61K31/5575 A61K31/192 A61K31/575 A61K31/502 C07D277/64
X	PATENT ABSTRACTS OF JAPAN vol. 1999, no. 12, 29 October 1999 (1999-10-29) -8 JP 11 199478 A (NAGOSHI HIROSHI), 27 July 1999 (1999-07-27) * abstract * --- -/--	18	
			TECHNICAL FIELDS SEARCHED (IntCl.7)
			G01N A61K C07D
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search: see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		21 May 2003	Tuyman, A
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.02.02) (p.04/07)

European Patent
OfficeINCOMPLETE SEARCH
SHEET CApplication Number
EP 01 30 5857Claim(s) searched completely:
1-17Claim(s) searched incompletely:
18

Reason for the limitation of the search:

Present claim 18 relates to compounds defined by reference to a desirable characteristic or property, namely that they modulate an activity of the CRTH2 receptor. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, only those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in the figures 7-10 form the object of the search (See "LACK OF UNITY OF INVENTION").

However, it is important to note that not for all the diseases mentioned in claim 18, a sufficient disclosure in the sense of Article 83 EPC appears to be present in the application, with regard to the use of the compounds as a medicament for the treatment thereof.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 01 30 5857

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (InCL7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	KINYA NAGATA ET AL: "SELECTIVE EXPRESSION OF A NOVEL SURFACE MOLECULE BY HUMAN TH2 CELLS IN VIVO" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 162, February 1999 (1999-02), pages 1278-1286, XP002933729 ISSN: 0022-1767 * the whole document *	15-17	
A	---	1-14	
X	NAGATA K ET AL: "CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s)" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 459, no. 2, 8 October 1999 (1999-10-08), pages 195-199, XP004260344 ISSN: 0014-5793 * the whole document *	15-17	
A	---	1-14	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	TANAKA K ET AL: "Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 MAR 2000, vol. 164, no. 5, 1 March 2000 (2000-03-01), pages 2277-2280, XP002224163 ISSN: 0022-1767 * the whole document *	1-17	
	---	-/--	

EPO FORM 1503 05 02 (p04c10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 5857

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE WPI Section Ch, Week 199010 Derwent Publications Ltd., London, GB; Class B05, AN 1990-070397 XP002241899 & JP 02 022226 A (ONO PHARM CO LTD), 25 January 1990 (1990-01-25) * abstract *	18	
X	US 3 885 041 A (ASPINALL RICHARD L ET AL) 20 May 1975 (1975-05-20) * the whole document * * claims 1-3 *	18	
X	PATENT ABSTRACTS OF JAPAN vol. 1999, no. 12, 29 October 1999 (1999-10-29) & JP 11 189537 A (KYOTO PHARMACEUT IND LTD), 13 July 1999 (1999-07-13) * abstract *	18	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	EP 0 253 094 A (GOH YASUMASA ; JAPAN RES DEV CORP (JP)) 20 January 1988 (1988-01-20) * abstract * * example 3 * * claims 1,2,7 *	18	
Y	BUNDY G L ET AL: "SYNTHESIS AND PLATELET AGGREGATION INHIBITING ACTIVITY OF PROSTAGLANDIN D ANALOGUES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 26, no. 5, 1 May 1983 (1983-05-01), pages 790-799, XP000650898 ISSN: 0022-2623 * the whole document *	18	
	---	-/--	

EPO FORM 153 01.82 (P/AC10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 5857

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	LEITINGER NORBERT ET AL: "The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets." THROMBOSIS RESEARCH, vol. 86, no. 4, 1997, pages 337-342, XP002241896 ISSN: 0049-3848 * the whole document * ---	18	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	EP 0 322 153 A (PFIZER) 28 June 1989 (1989-06-28) * abstract * ---	18	
X	FLOWER R J ET AL: "Inflammatory effects of prostaglandin D2 in rat and human skin" BRITISH JOURNAL OF PHARMACOLOGY 1976, vol. 56, no. 2, 1976, pages 229-233, XP008017424 * the whole document * ---	18	
X	MENCIU CECILIA ET AL: "New N-(pyridin-3-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents." JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 4, 25 February 1999 (1999-02-25), pages 638-648, XP002241897 ISSN: 0022-2623 * the whole document * ---	18	
	--- -/--		

EPO FORM 1502 03.02 (P/IntCl.7)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 5857

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (InCL.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994 YODONAWA SATOSHI ET AL: "Bronchial hyperresponsiveness to histamine induced by intravenous administration of 13,14-dihydro-15-keto-prostaglandin F-2alpha in guinea pigs." Database accession no. PREV199497246894 XP002241898 * abstract * & FOLIA PHARMACOLOGICA JAPONICA, vol. 103, no. 3, 1994, pages 91-99, ISSN: 0015-5691	18	
T	----- MONNERET GUILLAUME ET AL: "15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils." JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 304, no. 1, 20 January 2003 (2003-01-20), pages 349-355, XP008017457 ISSN: 0022-3565 * the whole document * -----	1-18	TECHNICAL FIELDS SEARCHED (InCL.7)

EPO FORM 1503 01.82 (P04C10)



European Patent
Office

Application Number
EP 01 30 5857

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 01 30 5857

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-17

Screening assays for identifying a compound that modulates the binding or activity of the CRTH2 receptor

2. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGD ring the compound being PGD2.

3. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGD ring the compound being PGD1.

4. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGD ring the compound being 13,14-dihydro-15-keto PGD2.

5. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGD ring the compound being 15(R) 15-methyl PGD2.

6. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGD ring the compound being 15(S)15-methyl PGD2.

7. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGD ring the compound being 16,16-dimethyl PGD2.



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 01 30 5857

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

8. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGD ring the compound being 15-deoxy-delta 12,14 PGD2.

9. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGF ring, the compound being PGF2a.

10. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGF ring, the compound being 13,14-dihydro-15-keto PGF2a.

11. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGF ring, the compound being 8-iso-15-keto PGF2a.

12. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGF ring, the compound being 9allb PGF2a.

13. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being a prostaglandin D2 agonist compounds based on a PGJ ring, the compound being 15-deoxy-delta 12,14 PGJ2.

14. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 01 30 5857

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

receptor the compound being a prostaglandin D2 agonist compounds based on a PGJ ring, the compound being delta 12 PGJ2.

15. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being the prostaglandin D2 agonist '4-chloro-2-(4-chloro-phenylsulfanyl)-phenyl-acetic acid

16. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being the prostaglandin D2 agonist 4-(3-Acetoxy-4,4,10,13,14-pentylmethyl-7-oxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta'a'phenanthrene-17-yl)-pentanoic acid

17. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being the prostaglandin D2 agonist (1-Benzothiazol-2-ylmethyl-5-fluoro-2-methyl-1H-indol-3-yl)-acetic acid

18. Claim : 18 (partially)

Use of a compound that modulates an activity of CRTH2 receptor the compound being the prostaglandin D2 agonist '3-(6-Hydroxy-benzothiazol-2-ylmethyl)-4-oxo-3,4-dihydro-phthalazin-1-yl-acetic acid

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 5857

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-05-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0114882 A	01-03-2001	AU 6598800 A	19-03-2001
		CA 2383135 A1	01-03-2001
		DE 1211513 T1	14-11-2002
		EP 1211513 A1	05-06-2002
		WO 0114882 A1	01-03-2001
		NO 20020837 A	22-04-2002
JP 11199478 A	27-07-1999	NONE	
JP 2022226 A	25-01-1990	NONE	
US 3885041 A	20-05-1975	NONE	
JP 11189537 A	13-07-1999	NONE	
EP 0253094 A	20-01-1988	DE 3788984 D1	17-03-1994
		DE 3788984 T2	18-08-1994
		EP 0253094 A2	20-01-1988
		JP 1898533 C	23-01-1995
		JP 6023106 B	30-03-1994
		JP 63107927 A	12-05-1988
		US 4824857 A	25-04-1989
EP 0322153 A	28-06-1989	AU 2733788 A	22-06-1989
		CA 1299181 A1	21-04-1992
		CN 1035116 A	30-08-1989
		DK 712388 A	31-07-1989
		EP 0322153 A2	28-06-1989
		FI 885886 A	22-06-1989
		HR 931304 A1	31-08-1996
		HU 56552 A2	30-09-1991
		IL 88729 A	23-07-1996
		JP 1211585 A	24-08-1989
		JP 1958310 C	10-08-1995
		JP 6092402 B	16-11-1994
		KR 9100438 B1	25-01-1991
		MX 14287 A	01-06-1993
		NZ 227441 A	21-12-1990
		PT 89268 A ,B	29-12-1989
		US 4939140 A	03-07-1990
		YU 230788 A1	31-10-1990
		ZA 8809519 A	29-08-1990

EPO FORM P449

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82